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ABSTRACT 
 
Stroke, ischemic or hemorrhagic, belongs among the foremost causes of death and 
disability worldwide. Massive brain swelling is the leading cause of death in large 
hemispheric strokes and is only modestly alleviated by the limited conservative 
treatments available today. Quite invasive surgical decompressive craniectomy is a 
promising option in selected patients. 
 
Aimed at fast restoration of circulation, thrombolysis with tissue plasminogen activator 
(TPA) is the only approved therapy in acute ischemic stroke, but fear of TPA-mediated 
hemorrhage is often a reason for withholding this otherwise beneficial treatment. In 
addition, recanalization of the occluded artery (spontaneously or with thrombolysis) may 
cause reperfusion injury (depending on severity and duration of the preceding 
ischemia) by promoting brain edema, hemorrhage, and inflammatory cell infiltration. A 
dominant event underlying these phenomena seems to be disruption of the blood-brain 
barrier (BBB). 
 
In contrast to ischemic stroke, no widely approved clinical therapy exists for 
intracerebral hemorrhage (ICH), which is associated with poor outcome mainly due to 
the mass effect of enlarging hematoma and associated brain swelling. 
Obviously, novel treatment strategies for brain swelling associated with large 
hemispheric strokes, TPA-associated hemorrhage, and spontaneous ICH are urgently 
needed.  
 
Mast cells (MCs) are perivascularly located resident inflammatory cells which contain 
potent vasoactive, proteolytic, and fibrinolytic substances encapsulated in their 
cytoplasmic granules. Experiments from our laboratory showed MC density and their 
state of granulation to be altered early following focal transient cerebral ischemia, and 
degranulating MCs were associated with perivascular edema and hemorrhage. This led to 
the hypothesis that MCs might be involved in regulation of BBB permeability, brain 
swelling, and neutrophil infiltration, as well as in hazardous TPA-mediated cerebral 
hematomas after stroke. Since the mass effect from increasing edema and hematoma 
volume are associated with poor outcome in ICH, the efficacy of MC-modulating 
strategies was tested also in this catastrophic condition. 
 
To examine the above hypothesis, the first question was whether MCs play a role in 
modulating BBB permeability, brain swelling, and neutrophil infiltration in a rat model of 
transient middle cerebral artery occlusion (MCAO) (I). Thereafter, in the same model, 
subsequent studies examined the potential role of MCs in TPA-mediated deleterious 
effects, and tested the effect of TPA on MCs in vitro (II). Finally, the role of MCs was 
studied in an autologous blood injection model of ICH (III). 
 
(I) Pharmacological MC stabilization led to significantly reduced ischemic brain swelling 
(40%) and BBB leakage (50%), whereas pharmacologically potentiated MC degranulation 
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raised these by 90% and 50%, respectively. Pharmacological MC stabilization also 
revealed a 40% reduction in neutrophil infiltration. Moreover, genetic MC deficiency was 
associated with an almost 60% reduction in brain swelling, 50% reduction in BBB 
leakage, and 50% less neutrophil infiltration, compared with control figures. 
 
(II) Experiments with TPA showed strong TPA-induced MC degranulation in vitro. In vivo 
experiments with post-ischemic TPA administration demonstrated 70- to 100-fold 
increases in hemorrhage formation (HF) compared with controls’ HF. HF was significantly 
reduced by pharmacological MC stabilization at 3 (95%), 6 (75%), and 24 hours (95%) 
of follow-up. Genetic MC deficiency again supported the role of MCs, leading to 90% 
reduction in HF at 6 and 24 hours. Pharmacological MC stabilization and genetic MC 
deficiency were also associated with significant reduction in brain swelling and in 
neutrophil infiltration. Importantly, these effects translated into a significantly better 
neurological outcome and lower mortality after 24 hours. 
 
(III) Finally, in experiments utilizing the ICH model, pharmacological MC stabilization 
resulted in significantly less brain swelling, diminished growth in hematoma volume, 
better neurological scores, and decreased mortality. Pharmacologically potentiated MC 
degranulation produced the opposite effects. Genetic MC deficiency revealed a beneficial 
effect similar to that found with pharmacological MC stabilization. 
 
In sum, the role of MCs in these clinically relevant scenarios is supported by a series of 
experiments performed both in vitro and in vivo. That not only genetic MC deficiency but 
also drugs targeting MCs could modulate these parameters (translated into better 
outcome and decreased mortality), suggests a potential therapeutic approach in a 
number of highly prevalent cerebral insults in which extensive tissue injury is followed by 
dangerous brain swelling and inflammatory cell infiltration. Furthermore, these 
experiments could hint at a novel therapy to improve the safety of thrombolytics, and a 
potential cellular target for those seeking novel forms of treatment for ICH. 
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1 INTRODUCTION 
 
Worldwide, ischemic stroke is one of the leading causes of disability and death. The 
major cause of death after a large hemispheric stroke is space-occupying brain 
swelling.1 Brain swelling occurs in about two-thirds of patients within 6 hours of 
ischemic stroke onset.2 The two main detrimental effects of swelling are (1) mass effect 
with compression of normal brain structures (herniation), and (2) decreased blood flow in 
the ischemic penumbra. Both effects damage the penumbra’s metabolism and facilitate 
its transformation into an infarction. Blood-brain barrier (BBB) damage increases 
tissue water content; the entry of serum proteins into brain tissue magnifies vasogenic 
edema and further swelling. Thus far, only limited conservative anti-edema treatment 
strategies exist. Invasive surgical decompressive craniectomy offers some benefit to 
selected patients, and experiments with hypothermia also seem promising. However, the 
possibilities to fight massive brain swelling are far from sufficient. 
 
Thrombolysis with tissue plasminogen activator (TPA) is the only approved 
pharmacological therapy for acute ischemic stroke, aiming to provide early recanalization 
of an occluded cerebral artery. For every 1000 patients treated with TPA within 3 hours 
after symptom onset, more than 140 will avoid disability, and the therapeutic window 
may extend to 4.5 hours.3 A major issue regarding this treatment is the risk for clinically 
relevant parenchymal hemorrhage, the etiology of which is not yet fully understood. 
In pooled analysis of placebo-controlled trials of thrombolysis, 6% of stroke patients 
developed a substantial brain hemorrhage, as compared to 1% in the placebo group.3 
Furthermore, TPA-treated patients with acute myocardial infarction have had a 1.1%,4 
and with pulmonary embolism a 3%5 risk for cerebral hemorrhage. 
 
Spontaneous recanalization or medical thrombolysis can evoke reperfusion injury (RI), 
which can worsen BBB leakage, leading to extravasation of plasma and of erythrocytes 
(formation of edema and of hemorrhage) and inflammatory cell infiltration. 
 
Intracerebral hemorrhage (ICH) accounts for 15% of all strokes in Western countries, 
and the percentage is even higher (20-30%) in Asian and black populations.6 ICH is 
associated with high mortality and disability, with only 40 to 50% of the patients 
surviving through the first year,7,8 many of them with chronic disability. Poor outcome 
results from direct tissue damage, especially in deep brain structures such as the basal 
ganglia, and the mass effect of the growing hematoma. In addition to the mass effect, 
the hematoma itself induces a number of early secondary changes in the surrounding 
tissue, including neuronal and glial cell death due to apoptosis9-11 as well as inflammation 
and vasogenic edema caused by disruption of the BBB.12,13 The compressive effect of 
perihematomal edema may contribute to secondary perihematomal ischemic injury, 
although its being ischemic is controversial. The mass effect of the growing hematoma 
and edema leads to displacement and disruption of brain structures and often to 
increased intracranial pressure (ICP). Currently, no approved effective acute medical 
treatment exists, and surgical evaluation of ICH was recently found non-beneficial.14 
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Mast cells (MCs) are tissue-based stationary effector cells that form a first-line defense 
against various challenges. They have been found in a variety of locations in the nervous 
system in different species, including humans,15 and appear to be concentrated in 
relatively few locations, which include the diencephalic parenchyma, particularly the 
thalamus, cerebral cortex, and the meninges, positioned in close proximity to potential 
cellular targets of mediator/cytokine action.16 Their metachromatic granules contain 
potent preformed vasoactive substances (e.g. histamine, bradykinin, leukotrienes (LT), 
and serotonin), proteolytic enzymes (e.g. chymase, tryptase, and cathepsin G), 
anticoagulants (heparin and chondroitin sulfate), and chemotactic factors (e.g. neutrophil 
and eosinophil chemotactic factor). MCs are well-known to be involved in allergic 
reactions but participate in various other conditions including inflammatory arthritis, 
coronary inflammation, interstitial cystitis, irritable bowel syndrome, multiple sclerosis, 
and migraine. Furthermore, they were found to play a role in angiogenesis, neoplasm 
formation, wound healing and tissue remodeling, blood clotting, tissue fibrosis, and 
ischemia-RI in the peripheral tissues. 
 
In the pilot microscopic experiments, MC density and their state of granulation was 
altered early following focal transient cerebral ischemia and degranulating MCs were 
frequently found in association with edema and hemorrhage formation. These findings 
together with characteristic perivascular location of MCs, the enormous potential to store 
and release potent mediators, and the ability of their proteases to degrade the basal 
lamina constituents17,18 led to hypothesis that MCs might be involved in the regulation of 
BBB permeability, brain swelling, neutrophil infiltration, as well as in the feared TPA-
mediated cerebral hemorrhages after stroke. In line with the assumed role in 
development of edema and hemorrhage, MC blocking was hypothesized to be beneficial 
in experimental ICH. 
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2 REVIEW OF THE LITERATURE 
2.1 Ischemic stroke 
 
Ischemic stroke originates from an abrupt decrease in the blood supply to a region of the 
brain, and results in a corresponding loss of neurologic function. The most common life-
threatening neurological disease, it is the third most common cause of death in 
developed countries, and the second most common in the world.19 It is estimated that 
one sixth of all human beings will suffer at least one stroke during their lives.20 Overall, 
stroke is killing more than 50/100,000 individuals annually in the USA, where its 
incidence is approximately 250/100,000 per year, costing around $40 billion annually.21 
In Finland, stroke mortality is around 40/100,000 per year, stroke incidence about 
270/100,000 per year, and costs approximately 6.1% of the whole health-care budget.19 
Ischemic stroke accounts for 80 to 85% of all cases of stroke. 
 
Stroke is not only the leading cause of death, but also of disability and long-term 
hospitalization, being second to Alzheimer’s disease as a cause of dementia.21 The 
earlier, rather nihilistic, view that acute ischemic stroke is untreatable has been replaced 
with some level of optimism based on the clinical use of thrombolysis and on some 
studies with neuroprotectants, although experience with clinical trials of the latter still 
offers no reason for much enthusiasm. However, multidisciplinary hospital treatment 
approaches, i.e., stroke unit therapy, have also been effective in reducing death and 
disability after stroke. 
 
Ischemic stroke is most commonly caused by atherosclerosis of extra- and intracranial 
arteries, embolism of cardiac origin, and small artery disease (lacunar stroke). 
Furthermore, ischemic stroke can be caused by vasculitides and dissections.  Risk factors 
for stroke include: advanced age, male gender, genetic predisposition, arterial 
hypertension, ischemic heart disease, hypercholesterolemia, thrombotic disorders (e.g., 
protein C-, protein S-, AT3-, and APC-deficiencies, lupus anticoagulans, elevated FVIII 
levels, FV-Leiden and FII-prothrombinogen mutation), diabetes mellitus, and smoking. In 
addition, excessive alcohol consumption, diet, physical inactivity, and obesity all play a 
role. 
 
2.1.1 Pathophysiology of cerebral ischemia 
2.1.1.1 Cerebral blood flow and ischemic cascade 
The brain represents only 2% of body weight but requires 15% of heart minute volume 
and 20% of the body’s oxygen supply. The brain’s energy source is glucose, the 
metabolism of which is 95% aerobic and 5% anaerobic; the latter can, however, be of 
short duration only. The brain has no stores of energy, and there exists a tight balance 
between oxygen and glucose supply. Should cerebral blood flow (CBF) in any area of 
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the brain be insufficient or absent, the subsequent loss of these two essential substances 
for oxidative phosphorylation disrupts the energy balance in brain cells and an ischemic 
cascade will be launched. This chain of spatial and temporal events following CBF 
reduction and energy failure includes free oxygen radical (e.g., hydrogen peroxide, 
hydroxyl radicals, and superoxide) formation, elevation of intracellular Ca2+ levels, 
excitotoxicity, and spreading depression, accompanied by ion changes, depolarization of 
cell membranes, and activation of enzymes with lytic activities, followed by the BBB 
disruption and inflammation.22 
 
Once the supply of energy substrates ceases or significantly decreases, lactate builds up 
via anaerobic glycolysis, free fatty acids are formed, and pH decreases, all potentially 
stimulating free radical formation.23 Energy-requiring calcium pumps fail with falling 
adenosine triphosphate (ATP) levels, resulting in perturbation of the Na+/K+-ATP-ase and 
Ca2+/H-ATP-ase pumps; the Na+-Ca2+ transporter is reversed. Even if sodium- and 
calcium-exchange pumps remove some of the Ca2+, three Na+ ions still enter for every 
two Ca2+ ions removed. 
 
The ionic changes described (elevation of intracellular Na+, Ca2+, Cl-, and elevation of 
extracellular K+ levels) lead to osmotic accumulation of water molecules inside the cell, 
called cytotoxic edema. Membrane depolarization and failure triggers the release of 
neurotoxic glutamate, with further increase in Ca2+ entry via glutamate receptors.24 
NMDA receptor-mediated glutamate neurotoxicity after cerebral ischemia may be at least 
partially mediated by excessive production of nitric oxide (NO).25 
 
Other sources of elevated intracellular levels of Ca2+ include: Ca2+ release from the 
endoplasmic reticulum, mitochondria, synaptic vesicles, and from Ca2+-binding proteins. 
Calcium activates a number of enzymes, such as protein kinase C, phospholipase A2, 
phospholipase C, cyclooxygenase, calcium-dependent NO-synthase, calpain, and various 
proteases and endonucleases affecting cellular integrity. 
 
Subsequently, formation of LT and free radicals (reactive oxygen, ROS, and nitrogen 
species) is launched. Free radicals react irreversibly with such cellular components as 
proteins, double bonds of phospholipids, and nuclear DNA26; they cause lipid 
peroxidation, membrane damage, dysregulation of cellular processes, and mutations of 
the genome. Oxygen radicals also serve as signaling molecules influencing inflammation 
and apoptosis.24 Both Ca2+- and free radical-mediated events are multiplied in association 
with reperfusion-mediated injury (see below). 
 
Crucial for the ultimate fate of the brain tissue is the severity and duration of the 
compromised CBF, calculated as cerebral perfusion pressure (CPP) divided by vessel 
resistance. CPP in turn is the difference between mean arterial blood pressure (MABP) 
and ICP. In humans, normal CBF value is approximately 50 ml per 100 g of brain tissue 
per minute. In the region with impaired blood supply, acidosis ensues, leading to local 
vasodilatation, hence reducing vessel resistance. The meaning of such autoregulation is 
    
14 
to maintain the CBF at sufficient levels. Ischemia caused by a drop in CBF to a third or a 
quarter can still be reversible; representing the ischemic threshold. On the other hand, 
CBF reduction below 10 ml / 100 g / min lasting for several minutes can already cause 
tissue damage, infarction (a histologic finding derived from a brain region that has 
suffered ischemic injury). 
 
Experimental work27 shows that 45 to 90 minutes of middle cerebral artery occlusion 
(MCAO) leads to swelling of astrocytes and endothelial cells (ECs), microvascular 
plugging by erythrocytes and polymorphonuclear leukocytes (PMNL) in regions with the 
lowest CBF, with minimal changes to the neuronal perikarya. Already 1 to 3 hours later, 
astrocytic changes spread to the cortex, and swollen and pale neurons appear in the 
striatum. Eosinophilic neurons (markers of necrosis) do not appear in the core of the 
ischemic lesion until more than 12 hours after MCAO and until 24 to 48 hours in the 
ischemic cortex. It is thus important, when acute treatment strategies are considered, to 
focus on salvageable ischemic tissue that is not irreversibly injured. 
 
2.1.1.2 The penumbra concept 
The region with CBF values below 10 to 15 ml / 100 g / minute represents the ischemic 
core; it undergoes rapid, anoxic cell death within minutes of ischemia onset with rapid (1 
hour or less) evolution into irreversible injury. Surrounding the core are the regions with 
CBF reduced to 15 to 35 ml / 100 g / minute, showing much slower (hours) evolution. 
These regions are potentially salvageable, depending on the duration and magnitude of 
perfusion deficit, collateral blood flow, temperature, glucose levels, and acidosis.28 Such 
tissue surrounding the ischemic core is called the ischemic penumbra. The penumbra is 
considered potentially salvageable tissue-at-risk and differs from the core in terms of the 
process of cellular injury and cell death. While necrosis is more dominant in the core 
tissue, both necrosis and apoptosis are involved in penumbral cell death, and apoptosis 
alone seems to be involved in cell death further away from the core.29 
 
Apoptosis can be triggered by a number of processes, including excitotoxicity, free-
radical formation (damaging cellular lipids, proteins and nucleic acids), inflammation, 
mitochondrial and DNA damage, and cytochrome c release from mitochondria.29 
Apoptotic cell morphology differs from the necrotic type. Cellular necrosis includes 
cellular swelling, loosening of cellular architecture by cytoskeletal disruption, breakdown 
of cellular organelles, and denaturation of cytoplasmic proteins followed by an 
inflammatory response. In contrast, apoptosis is characterized by cellular shrinkage down 
to 60% and marked condensation of chromatin in the nucleus. In addition, apoptotic 
features include membrane blebbing, and fragmentation of the cell by separation of the 
protuberances to form multiple small membrane-bound bodies that contain intact 
organelles or dense clumps (apoptotic bodies) or both.29,30 Apoptotic cells are rapidly 
removed by macrophage- and microglia-mediated phagocytosis without eliciting an 
inflammatory reaction, contrary to the PMNL-mediated phagocytosis of necrotic cells.30 
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Recently, it was suggested that both necrosis and apoptosis are two extreme poles of 
cellular death after ischemic stroke, “aponecrosis”.26 Even if the features of apoptosis are 
wellknown from experimental work, few studies demonstrate apoptotic features in human 
stroke.30-32 As mentioned, apoptosis seems to occur after milder ischemic injury, 
particularly in association with the penumbra.29 
 
The process of recruiting the penumbral tissue into the core and of infarct propagation 
was, experimentally, found to involve recurrent waves of depolarization (an energy-
consuming process called spreading depression), which start within the core and extend 
outwards to surrounding tissue.33,34 Each wave of depolarization increases infarct volume 
by 20% during the first 3 hours after vessel occlusion.34 The most likely source for the 
depolarization is the elevated extracellular K+ level and increase in the glutamate release 
at the boundaries between the ischemic core and the penumbra.33 
 
The penumbra can be identified by imaging techniques and some studies suggest its 
existence for up to 48 hours in individual patients.35,36 In magnetic resonance imaging 
(MRI), the penumbra corresponds to a mismatch between perfusion- and diffusion-
weighted imaging (DWI).28,37 Hossmann and coworkers38 found that 7 hours after onset 
of ischemia, the DWI-based infarct region was almost identical to the severe ATP-decline 
region. With different durations of ischemia, those authors found the DWI changes 
already to be maximal at 105 minutes, but the severe ATP-decline region was noticeably 
smaller by that time; ATP decline corresponded well with CBF decline. 
 
Utilizing positron emission tomography (PET), Heiss and coworkers28 described the 
penumbra in terms of hypoperfusion (reduced CBF), preserved cerebral metabolic rate of 
oxygen (CMRO2), and increased oxygen extraction fraction (OEF). Altogether, they 
defined four different patterns of PET findings: autoregulation (increased cerebral blood 
volume (CBV) to maintain CBF), oligemia (decreased CBF and increased OEF to maintain 
CMRO2), ischemia (decreased CBF and decreased CMRO2 despite increased OEF), and 
irreversible injury (very low CBF and CMRO2). In that work, pattern 3 was widely present 
at 1 hour after MCAO, at 4 hours pattern 4 was common in the central zone and pattern 
3 peripherally, and at 24 hours everywhere had nearly completely pattern 4 (highly 
correlating with postmortem infarct size). 
 
When CMRO2 below 1.5 ml / 100 g / minute was used to define severely ischemic tissue 
in a PET MCAO study in primates,39 no significant change was found in the volume of 
tissue below this value in the ischemic hemisphere over the initial 7 hours, but the 
volume of such tissue significantly increased at 24 hours and was even larger at 14 days, 
suggesting that evolution of focal ischemic injury continues in primates over a longer 
time period. Similar results from a human study40 suggest that many stroke patients 
have potentially salvageable ischemic tissue within 24 hours after onset. In another PET 
study,41 CBF was calculated in 10 patients within 3 hours of onset of ischemia to define 
critically hypoperfused tissue, penumbral tissue, and sufficiently perfused tissue. After 2 
to 3 weeks, the authors calculated the relative contribution of these regions to final 
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infarct volume as defined by MRI. Almost 70% of the final infarct volume was caused by 
initially critically hypoperfused tissue, 18% by penumbral tissue, and 12% by initially 
sufficiently perfused tissue, demonstrating that acute critical CBF decline is the 
predominant cause of infarction. This in turn justifies a rather aggressive approach 
aiming at rapid recanalization of the occluded artery and reperfusion of ischemic brain 
tissue. 
 
2.1.2 Neuroprotection and recanalization 
2.1.2.1 Neuroprotection 
Several successful experimental attempts aimed to reduce infarct size and outcome. In 
the clinical setting, however, apart from approved intravenous (iv) thrombolysis (see 
below), many of the phase I to III clinical trials did not reproduce the exciting laboratory 
findings for pharmacologic neuroprotection. Among the numerous drugs found to be 
clinically ineffective were NMDA antagonists, GABA agonists, free radical scavengers, 
anti-adhesion molecules, calcium antagonists, and agents that promote cell membrane 
stabilization (citicoline). The reason for the discrepancies between experimental and 
clinical data may lay in the susceptibility of animals to ischemia and to neuroprotectants, 
adverse effects of neuroprotectants, differences in pharmacokinetics, and in the time 
windows and delayed treatment in human trials.24 
 
Thus, it is possible that glutamate pathway-related neuroprotectants can be effective 
when used within a shorter time window and, interestingly, a pilot trial of FAST MAG (The 
Field Administration of Stroke Therapy-Magnesium) with iv magnesium (acting 
presumably as an NMDA receptor blocker), was found beneficial.42 In contrast, the 
parallel study did not confirm the positive results in terms of primary outcome, i.e., 
mortality and 90-day disability.43 However, in the parallel study, most of the patients 
received treatment beyond 3 hours (up to 12 hours) of symptom onset, and the FAST-
MAG investigators received permission to start a phase III trial with magnesium 
administration within 1 to 2 hours of symptom onset. 
 
Another positive clinical trial was SAINT-I (Stroke-Acute Ischemic NXY Treatment I),44 
testing a free radical trapping agent NXY-057, which was found effective experimentally. 
This trial found improved primary outcome (90-day disability), but it did not significantly 
improve other outcome measures (neurological function evaluated by National Institutes 
of Health stroke scale score); therefore, results of the phase II trial (SAINT-II) were 
eagerly awaited. However, the SAINT-II trial was negative and did not meet its primary 
outcome in stroke-related disability.45 
 
Based on preliminary evidence, early induction of hypothermia may prove beneficial in a 
clinical situation.46 It seems likely that the neuroprotective approaches per se cannot be 
beneficial if blood circulation is not restored at least to some degree. They could play a 
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role in widening the therapeutic window for successful recanalization/reperfusion or in 
lessening cellular death (e.g., inhibiting apoptosis) following recanalization. 
 
2.1.2.2 Recanalization and thrombolysis 
Acute critical changes in CBF disturbances offer a major contribution to cumulative 
ischemic brain damage.41 Thus—apart from the unrivaled “time window” for stroke 
treatment, prevention—the most suitable and beneficial moment to reverse the drastic 
consequences of stroke is in the hyperacute phase before the tissue-at-risk evolves into 
infarction. Recent meta-analysis of angiography- or transcranial Doppler-monitored 
studies in humans reported that spontaneous recanalization occurs in approximately 
one-quarter of patients within 24 hours, and in approximately half the patients up to 1 
week after stroke.47 Therapeutic recanalization is reported to have a success rate of 
46% for intravenous fibrinolysis, 63% for intra-arterial and 67% for combined 
intravenous/intra-arterial thrombolysis, and 84% for mechanical thrombolysis.47 
 
To date, the most effective treatment for acute ischemic stroke is early reperfusion of the 
ischemic brain to salvage the penumbral tissue, reduce final infarct size, and improve 
functional outcome. The only proven reperfusion therapy is the administration of iv TPA 
within 3 hours of symptom onset in selected acute ischemic stroke patients. For every 
1000 patients treated with TPA within 3 hours after symptom onset, more than 140 will 
avoid disability, and the therapeutic window may extend to 4.5 hours.3 In that pooled 
analysis (based on all major randomized placebo-controlled trials of TPA for acute stroke 
including more than 99% of all TPA-treated patients), TPA treatment reduced death and 
disability at 3 months compared with results for the placebo group. According to the 
investigators, it is disappearance of the ischemic penumbra that is responsible for onset-
to-treatment-dependent beneficial outcome. 
 
While 15% of ischemic stroke patients admitted to the Helsinki University Central 
Hospital receive thrombolysis,48 fear of TPA-associated hemorrhage may in part explain 
why only a mean of 2 to 5% of ischemic stroke patients as of yet receive this beneficial 
treatment even in specialized stroke centers worldwide.49,50 Despite the clear benefit of 
early thrombolysis, tight inclusion and exclusion criteria exist as to patients to be treated, 
since TPA treatment is associated with an almost 6% risk (compared with 1% with 
placebo) of clinically relevant parenchymal hemorrhages.3 Such hemorrhages were 
not associated with onset-to-treatment time (3-6 hours vs < 3 hours), but rather with 
TPA-treatment per se and with age of patient.3 Risk for any hemorrhage in that analysis 
was 11%, including asymptomatic intracranial hemorrhage in patients treated with TPA. 
Moreover, patients treated with TPA for acute myocardial infarction or pulmonary 
embolism were at a 1.1%4 and 3%5 risk for cerebral bleeding, respectively. 
 
Hemorrhagic transformation is a frequent consequence of ischemic stroke even without 
thrombolysis. Up to 30 to 40% of all ischemic strokes51,52 and 60% of embolic strokes53 
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undergo spontaneous hemorrhagic conversion, i.e., transformation of a bland 
(anemic) infarct into a hemorrhagic one. The two types of hemorrhagic transformation 
are hemorrhagic infarction (without clinical deterioration) and parenchymal 
hemorrhage (clinically relevant) (Table 1). 
 
The percentage of parenchymal hemorrhages in different studies differs according to the 
criteria selected. Recently published and performed under European Union regulations, 
the SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) 
study54 reports a proportion of 1.7% patients with symptomatic (deterioration in National 
Institutes of Health stroke scale score of ≥4) ICH at 24 hours. There, hemorrhage was 
defined as a dense blood clot exceeding 30% of the infarct volume with a significant 
space-occupying effect (parenchymal hemorrhage type 2, Table 1). However, the 
proportion of patients with symptomatic ICH increased to 7.3% using the criteria for the 
National Institutes of Neurological Disorders and Stroke trial and for the Cochrane. These 
included patients with any degree of hemorrhage on computed tomography (CT) 
combined with any neurological worsening. 
 
The European Cooperative Acute Stroke Study investigators defined symptomatic ICH as 
any hemorrhage plus a neurological deterioration in a National Institutes of Health stroke 
scale score of ≥4. By this definition, the proportion of patients with symptomatic ICH in 
SITS-MOST was 4.6%. While it is most likely that—including parenchymal hemorrhage 
type 2 (Table 1)—the SITS-MOST will detect major symptomatic ICH, the Canadian 
counterpart of SITS-MOST recently reported that parenchymal hemorrhage type 1 and 
hemorrhagic infarction type 2 (Table 1) were also significant predictors of poor 
outcome.55 Despite variation in reported TPA-mediated hemorrhagic events, the SITS-
MOST registry justifies administration of TPA for selected acute ischemic stroke patients. 
 
 
Table 1. Definitions of cerebral bleeding 
 
National Institutes of Neurological Disorders and Stroke 
HI acute infarction with punctuate or variable hypodensity/hyperdensity, with an 
indistinct border within the vascular territory 
PH typical homogeneous, hyperdense lesion with a sharp border with or without 
edema or mass effect 
European Cooperative Acute Stroke Study 
HI petechial infarction without space-occupying effect 
HI1 small petechiae 
HI2 more confluent petechiae 
PH hemorrhage with mass effect 
PH1 < 30% of infarcted area with mild space-occupying effect 
PH2 > 30% of infarcted area with significant space-occupying effect 
HI, hemorrhagic infarction; PH, parenchymal hemorrhage 
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If no recanalization is achievable, potential unfavorable actions of TPA may overwhelm 
the purported beneficial effects of the treatment. Hemorrhages and vascular RI (the BBB 
disruption, brain swelling, and neutrophil infiltration) can devastate prognosis even 
following successful clot lysis. TPA is a pleiotropic molecule. It is a fibrin-specific 
activator for conversion of the precursor molecule plasminogen to active plasmin. 
Plasmin, in turn, dissolves fibrin-based clots. In addition to its role in clot lysis, TPA may 
also possess signaling and protease action in the vasculature.50 Such effects can mediate 
formation of hemorrhages in the brain parenchyma. 
 
Some data suggest, that TPA and plasmin are potentially neurotoxic, should they reach 
the extracellular space56; if TPA is administered promptly after ischemia onset, the BBB 
remains intact, and exogenous TPA remains within the vascular space and is eliminated 
within minutes due to its short half-life in circulation. Experiments with TPA-deficient 
mice57 showed increased TPA-associated neuronal damage in the hippocampus. Concern 
was, however, raised about that study, since under normal conditions, endogenous TPA 
does not lead to degeneration of the hippocampus.58 
 
It seems that the beneficial effects of TPA-induced early thrombolysis and restoration of 
CBF are overwhelmingly greater than the potential detrimental effects such as 
neurotoxicity (cleavage of the NMDA R1 subunit, amplification of intracellular Ca2+ 
conductance), BBB disruption, edema, and hemorrhage (matrix metalloproteinases, 
MMPs), and inflammatory exacerbation of ischemic insults (accumulation of PMNL and 
free radicals).56,59 Interestingly, the protease actions of TPA are involved in extracellular 
matrix (ECM) and parenchymal matrix modifications, which may mediate neuronal 
precursor migration as well as neurite and axonal extension60,61 and thus affect neuronal 
plasticity during recovery from stroke.50 
 
Indeed, the effects of TPA in the setting of cerebral ischemia are manifold, difficult to 
predict, and dependent on the stage of evolution of the imminent infarction as well as on 
the success in opening the occluded cerebral artery. 
 
2.1.2.3 Reperfusion injury 
In ischemic stroke, once the recanalization of the occluded artery has occurred either 
spontaneously or following a therapeutic intervention, the ensuing reperfusion delivers 
oxygen and glucose to the tissue and removes waste substances that have accumulated 
during ischemia. On the other hand, during reperfusion of the previously ischemic tissue, 
functionally impaired mitochondria are unable to use superfluous delivery of oxygen in 
electron transport, which may result in reduction in cellular ATP levels, production of 
ROS, activation of apoptosis, and initiation of inflammatory processes.22 
 
Such a cascade of events can lead to deterioration of the tissue state; hence the term 
reperfusion injury.62,63 Besides free radicals, several other substances have been 
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suggested to play a role in the cascade of RI, including excitatory amino acids, free fatty 
acids, cytokines, expression of endothelial adhesion molecules, Ca2+ influx, and protein 
kinases.22,62-64 A critical step is the remodeling of the microvascular structure. Free 
oxygen radicals may cause peroxidation of lipids in the cell membranes, resulting in the 
failure of membrane ATP-ase, changes in cellular homeostasis, and elevation in the 
concentration of free fatty acids.64 
 
The existence and nature of RI has been a subject of debate. Recanalization does not 
always lead to noticeable RI and, importantly, recanalization does not automatically 
mean adequate tissue reperfusion.65 Effective reperfusion may not occur despite 
recanalization because of complex phenomena leading to “no-reflow” such as migration 
of emboli, secondary thrombosis, hemorrhage, edema, swelling of the intima, 
microvascular plugging by PMNL and platelets, and tissue factor-mediated coagulation 
system activation in the microvessels.66 
 
Despite some controversies about RI (see below), a time window may exist, during which 
reperfusion is clearly beneficial, with only the late reperfusion being associated with RI. 
Early reperfusion (up to 90 minutes after MCAO) was beneficial in studies in rats,67 with 
later reperfusion being harmful, causing BBB disruption, formation of vasogenic edema 
and hemorrhage, neutrophil infiltration, and larger infarcts.62,68-71 The existence of such a 
time window for reperfusion to occur is very important from the clinical point of view, 
especially with respect to thrombolytic treatment and possible “anti RI” treatment 
strategies. 
 
Controversy exists as to hyperperfusion and RI as judged by differences between the 
human and experimental data including rodents,69 cats,72 or nonhuman primates.73 In 
human studies by Marchal and coworkers,74-76 early post-ischemic hyperperfusion was 
not seen to be deleterious for tissue survival; in one of their studies, they found almost 
no overlap between hyperperfusion as seen in initial PET and infarct area seen on final 
CT.76 However, patients with hemorrhage were excluded from this study; hence it is 
unknown whether hyperperfusion contributed to hemorrhage. Furthermore, normal CT 
rules out pan-necrosis, but not selective neuronal loss.77 In their studies, Marchal and 
coworkers74-76 suggested that when observed 5 to 18 hours after stroke onset, focal 
hyperperfusion without already extensive irreversible tissue damage invariably predicts 
minute (or absent) infarcts and excellent spontaneous recanalization/reperfusion, which 
presumably occurs sufficiently early to prevent ischemic tissue from evolving into 
infarction. 
 
Heiss and coworkers78 found hyperperfusion sometimes to be associated with incomplete 
infarction or selective neuronal loss and confirmed72 the findings of Marchal and 
coworkers74-76 that early hyperperfusion is beneficial and is a marker of good outcome. 
Hyperperfusion does not always occur after recanalization, however. In one study of 14 
patients, only 2 showed an area of hyperperfusion in relation to the recanalization noted 
in their angiograms.79 Furthermore, even though Olsen and coworkers80 noticed frequent 
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hyperperfusion 1 to 4 days after symptom onset, still only 4 of their 12 patients showed 
hyperperfusion within 48 hours and only 1 patient within 10 hours. 
 
Von Kummer and coworkers65 questioned the role of RI in the clinical setting even in 
cases of delayed recanalization (8-24 hours after symptom onset) and presumed that it 
was the collateral blood supply that kept the brain tissue viable more than 8 hours after 
MCAO in those who showed delayed recanalization. Similarly, Marchal and coworkers 
suggested that reperfusion does not contribute much to tissue injury and that RI 
develops only in the case of already irreversibly injured tissue, which would no longer 
benefit from recanalization/reperfusion anyway, nor from possible RI treatment. 
 
Still, the results of Marchal and coworkers can be interpreted in a way that early, not 
late, reperfusion is beneficial, fitting with the assumed existence of the time window for 
intervention. Indeed, Marchal and coworkers admit that RI may develop with late 
hyperperfusion and that selective neuronal loss occurs in areas with early post-ischemic 
hyperperfusion. 
 
Furthermore, Warach and Lawrence81 reported RI to be exacerbated by thrombolysis in 
human ischemic stroke and suggested that early BBB disruption in humans may be a 
crucial target for adjunctive therapy to reduce the complications of RI/thrombolysis, to 
broaden the therapeutic window, and to improve clinical outcome (Figure 1). Surely, 
further research is needed to find how wide this time window is and how it could 
potentially be modified. Von Kummer and coworkers65 suggested two critical periods for 
the time window, the first of which may already be closed by the time the patient is 
admitted, as it is influenced by the extent of primary ischemia. The second period seems 
to be open for an uncertain length of time, being influenced by collateral blood flow and 
cerebral oxygen supply. 
Transient focal cerebral ischemia
Reperfusion
(spontaneous or TPA-mediated)
Saved tissue Reperfusion injury
Beneficial effect Detrimental effect
• BBB leakage
• brain swelling
• hemorrhage
• neutrophils
 
Figure 1. Reperfusion injury
    
22 
It seems that more important than level of hyperperfusion after recanalization is the 
severity of CBF drop during the preceding ischemia together with the duration of 
ischemia. Aronowski and coworkers62 found that reperfusion of long-lasting severe 
ischemia in rats (480 and 1080 minutes) no longer led to RI (perhaps the changes 
caused by ischemia were already maximally detrimental), and it is generally accepted 
that reperfusion after very severe ischemia (no residual CBF) does not lead to RI. 
Clearly, reperfusion presents a dilemma, as on the one hand it can reduce lesion volume 
and edema formation, but on the other hand, it may promote BBB damage, with 
subsequent formation of vasogenic edema and hemorrhage and neutrophil infiltration. 
 
2.1.3 Blood-brain barrier and basal lamina disruption 
 
The microenvironment of the CNS and integrity of the cerebral microvasculature is 
secured by two barriers: the BBB and basal lamina (Figure 2, bottom left and right). 
The former is composed of tight interendothelial-cell junctions of capillary and 
postcapillary venules. Tight junctions form a continuous network of parallel 
intramembrane strands of protein connected to the internal actin cytoskeleton.82 Several 
integral transmembrane proteins exist (claudin, occludin, and junction adhesion 
molecule) as well as cytoplasmic accessory proteins that belong to the zona occludens 
family and others such as AF6 and cingulin. 
 
The second barrier, the basal lamina, is a specialized part of the ECM that connects the 
EC to the adjoining cell layers and the smooth muscle of the media. The constituents of 
the basal lamina include the matrix proteins laminin, collagen type IV (both connected 
by entactin), fibronectin, thrombospondin, various proteoglycans, and heparan 
sulfates.71,83 The basal lamina is connected to the endothelium by fibronectin and 
laminin. 
 
Continuous disappearance of antigens of the three main constituents of the basal lamina 
(laminin, fibronectin, and collagen type IV) occurs very early after ischemia onset, when 
the basal lamina loses its integrity.84,85 Some evidence exists (see below) that 
proteases, most importantly MMPs and PAs, are involved in the disruption of the ECM, 
which leads to changes in the vessel wall, and may loosen the matrix around cells. 
Recently, a role for another type of proteases (cathepsins) in degrading matrix 
components was demonstrated.86 
 
MMPs comprise a large family of proteolytic enzymes, zinc endopeptidases, which are 
secreted in an inactive form and require mediation by other proteases. They are divided 
into five groups, the collagenases (MMP-1, MMP-8, and MMP-13), gelatinases (MMP-2 and 
MMP-9), stromelysins (MMP-3, MMP-7, MMP-10, and MMP-11), elastases (MMP-12), and 
the membrane-type MMPs (MMP-14, which activates pro-MMP-2).87 Tissue inhibitors of 
metalloproteinases (TIMPs) are endogenous regulators of MMP activity.87 Gelatinase A 
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Figure 2. Schematic illustration of the neurovascular unit (middle) and the components of the 
blood-brain barrier (bottom left) and the basal lamina (bottom right). ECM=extracellular matrix, 
ZO=Zona occludens, AF6=afadin, 7H6=tight junction associated phosphoprotein. (Bottom left 
image adopted in part from del Zoppo, GJ et al. Arterioscler Thromb Vasc Biol 2006; 26:1966-1975 
and Huber JD et al. Trends Neurosci 2001; 24:719-725.
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(MMP-2) and B (MMP-9) are the largest members of the MMP family and are to date the 
only gelatinases identified.88 
 
Activated MMPs can degrade most protein constituents of the neurovascular matrix: 
collagen, elastin, fibronectin, vitronectin, and gelatine.89 Experimental data show 
involvement of the gelatinases MMP-2 and MMP-9 in degradation of components of the 
basal lamina followed by BBB disruption and development of edema and 
hemorrhage.71,84,90-94 Such digestion of the endothelial basal lamina has occurred as early 
as 2 hours after transient ischemia.84 Clinical data revealed some level of a positive 
correlation between degree of brain edema and level of MMP-9 in the cerebrospinal fluid 
(CSF).95 
 
Furthermore, MMP-mediated disruption of the tight junction proteins occludin and claudin 
occurs, and a MMP inhibitor has reduced BBB disruption 3 hours after transient focal 
cerebral ischemia.94,96 These results suggest rather early BBB disruption after transient 
MCAO. Fujimura and coworkers97 found activated MMP-9 to appear as early as 3 hours 
after 60 min of transient MCAO, and a significant increase in pro-MMP-9 occurred in a 
time-dependent manner during reperfusion, the latter was not caused by the reduction in 
TIMP-1. 
 
Neutralizing free oxygen radicals (their main source being arachidonic acid released from 
cell membrane phospholipids) by spin traps or scavenger enzymes (superoxide 
dismutase, catalase) reduces BBB disruption.98,99 Furthermore, mice lacking superoxide 
dismutase are highly susceptible to focal cerebral ischemia-reperfusion with more 
vasogenic edema and higher mortality than in their wild-type (WT) littermates.100 Free 
radicals may influence MMPs, either through activation of the latent forms or by mRNA 
induction.89 
 
Besides having detrimental consequences, MMP activity and BBB disruption can also play 
a physiologic role in neovascularization, angiogenesis, and reconstruction-
neurogenesis.1,101,102 MMPs can be induced in a variety of cells in the CNS, including 
ECs,103 astrocytes,104 oligodendrocytes,105 microglia,106 neurons,107 and MCs.88 MCs are 
also a major source of MMP-1,108 MMP-2,109 MMP-3,110 and MMP-9.109,111,112 
 
Multiple levels of cell-cell and cell-matrix interactions influencing cerebral 
microvasculature integrity led to a proposal of a neurovascular unit,26 including 
endothelium, basal lamina, ECM, neurons, astrocytes fibers and end feet, pericytes, and 
microglia (Figure 2, middle). Matrix adhesion receptors, e.g., the integrins and 
dystroglycan, are expressed in the microvasculature, by neurons, and by the glial cells, 
as recently reviewed.113,114 Integrins are cell-surface transmembrane αβ heterodimers 
that recognize matrix ligands,115 whereas dystroglycan is a single αβ heterodimeric 
transmembrane receptor which forms a link between the intracellular cytoskeleton and 
the ECM.116 Integrins α1β1 and α6β4 disappear rapidly—within 2 hours of ischemia.
85,117 
Complex interactions within the neurovascular unit suggest the need for a multilevel 
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approach for therapeutically targeting the loss of microvascular integrity shown by basal 
lamina dissolution and BBB disruption and its consequences such as formation of edema 
and hemorrhage, and inflammatory cell infiltration. 
 
2.1.3.1 Ischemic brain edema: characteristics and treatment 
Evolution of cerebral infarction is invariably associated with development of some degree 
of brain edema. By definition, brain edema represents abnormal accumulation of fluid 
within the brain parenchyma, leading to volumetric enlargement of the tissue.118 Space-
occupying brain swelling is one of the major determinants of patient survival beyond the 
first few hours after a major stroke, being the leading cause of death after the large 
hemispheric middle cerebral artery (MCA) strokes,1,24 which account for 15 to 20% of all 
MCA strokes.119 In addition, brain swelling is a major prognostic factor in cerebellar 
strokes. 
 
Early ischemic brain swelling is already present in two-thirds of patients during the first 3 
to 6 hours,2 becomes evident within the first 24 hours, and peaks at 72 hours.1 Mortality 
from progressive edema in patients with large hemispheric strokes is approximately 
80%.119,120 Brain edema aggravates the ischemic process by its volumetric effect’s 
causing local compression of the microcirculation, rise in ICP, dislocation of parts of the 
brain (herniation), and decreased CBF in the ischemic penumbra. All these effects 
damage the penumbral metabolism and facilitate its transformation into infarction. 
 
Ischemic brain edema is a combination of two types of edema: cytotoxic (cellular) and 
vasogenic.118 Cytotoxic edema evolves over minutes to hours and may be reversible, 
whereas the vasogenic phase occurs over hours to days, and is considered an irreversibly 
damaging process. Cytotoxic edema is characterized by swelling of all the cellular 
elements of the brain. It represents a shift of water from the extracellular to intracellular 
compartment, accompanied by shrinkage of the former. In the presence of acute cerebral 
ischemia, neurons, astrocytes, and ECs swell within minutes of hypoxia due to failure of 
ATP-dependent ion (Na+ and Ca2+) transport. With the rapid accumulation of Na+ within 
cells, water follows to maintain osmotic equilibrium. Increased intracellular calcium 
activates phospholipases and the release of arachidonic acid, leading to the release of 
oxygen-derived free radicals and to cell death. 
 
Should the ischemia take only a short time, the disturbed membrane potential may 
recover. However, cellular swelling and Ca2+ influx are considered to cause irreversible 
damage to the cell.23 Vasogenic edema is characterized by an increase in extracellular 
fluid volume due to increased permeability of brain capillary ECs to macromolecules 
(e.g., albumin, IgG, and dextran). Normally, the entry of plasma protein-containing fluid 
into the extracellular space is limited by tight EC junctions, but after BBB disruption, 
water, Na+, proteins, and blood constituents enter the extracellular space. The degree of 
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edema is, like the BBB disruption, influenced by the severity and duration of ischemia 
and reperfusion.69,121 
 
The skull offers rather limited possibility to expand. An increase in volume of any 
intracranial structure (brain, CSF, and blood) will lead to an increase in ICP or shift one 
compartment of the brain, thus compressing others. Further increase in ICP promotes 
brain shifts and distortion (herniation), resulting in compression of neurons, nerve 
tracts, and cerebral arteries.  Herniation usually occurs in the tentorium, the foramen 
magnum, and the falx. Continuously increased ICP causes long-lasting ischemia and 
irreversible damage to brain cells. When ICP rises, CPP and CBF are reduced by 
autoregulatory vasodilatation. When CPP drops below a critical threshold of about 50 to 
60 mmHg, maximal vasodilatation takes place, and autoregulation fails. CBF is further 
compromised, and worsening ischemia aggravates edema. 
 
Several treatment strategies have been utilized in targeting ischemic brain edema and 
elevated ICP. Clinically, osmotherapy (mannitol, hypertonic saline (HS), glycerol, and 
sorbitol), steroids, barbiturates, hyperventilation, elevated head position, tromethamine, 
indomethacin, and furosemide have all been used with variable success. Hypothermia 
and invasive decompressive craniectomy seem promising. 
 
Osmotherapy has served for the management of patients with elevated ICP since the 
early 1960s, yet its use remains controversial. The rationale of its use comes from the 
existence of the intracellular and extracellular compartment, with the latter further 
divided into intravascular and interstitial compartments. Mechanisms of ICP reduction by 
osmotherapy include water extraction from the brain, raising of blood pressure (resulting 
in autoregulatory vasoconstriction and a fall in CBV), and lowering of serum viscosity 
(leading to reduced CBV). 
 
Mannitol neither crosses the cell membrane nor the intact BBB, i.e., it remains 
intravascular and can extract intracellular and interstitial water. However, mannitol can 
cross the injured BBB, arousing concern that it might accumulate within injured tissue, 
causing brain edema and midline shifts (not confirmed by others122) and shrinkage of the 
non-infarcted brain tissue.123 This would cause further expansion of the ischemic 
hemisphere and potentially aggravate the midline shift. However, Diringer and Zazulia124 
proposed that a) it is probably fiction that mannitol accumulates in the injured brain; b) 
it is probably fact that mannitol shrinks only the normal brain; c) it is fiction that 
mannitol increases midline shift; that osmolality can serve to monitor its administration; 
that mannitol should not be administered if osmolality exceeds 320 mOsm; and d) it is 
unknown whether HS and mannitol are equally effective. Evidence is generally lacking for 
the efficacy of mannitol, but still the American Heart Association recommendeds it to 
treat post-stroke edema. Nevertheless, Cochrane analysis125 lacked sufficient evidence 
for a general recommendation as to mannitol use. 
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Several human studies have compared HS with mannitol, but it is difficult to reach clear 
conclusions, since osmotically equivalent doses (this means 23.4% saline and mannitol) 
of the two agents were rarely used, and HS was used in cases refractory to mannitol. 
Prophylactic use of osmotherapy before onset of elevated ICP has not been addressed.  
 
The BBB has a higher osmotic reflection coefficient for Na+ and Cl- than for mannitol, so 
saline crosses into the interstitial space but is excluded from the intracellular 
compartment. In stroke patients, HS (7.5% + 100 ml hydroxyethyl starch) and 40 g 
mannitol reduced the increased ICP, the former approach significantly lowering ICP more 
rapidly and effectively (for 16 of 16 patients) and increased CPP significantly (although 
not as much as did mannitol).126 In another study by the same group, HS (10%) was 
beneficial after failure of other medical therapies including mannitol.127 However, almost 
no evidence exists for the use of HS in ischemic stroke, since systematic trials are 
lacking. 
 
In a study with ultrasound monitoring of ICP therapy with mannitol iv, sorbitol iv, and 
glycerol po (50 g each), the pulsatility index was significantly lowered in all groups on 
both the infarcted and healthy side, with no significant differences between the 
substances or sides. Glycerol showed the longest duration of effect, and all substances 
raised minimal flow velocity (glycerol showing the greatest increase), i.e., edema 
reduction.128 Although glycerol 10% was beneficial in some studies, Cochrane review129 
suggests just short-term benefit, no long-term, and does not support its use as standard 
therapy. 
 
Regarding treatment with steroids, the classical categorization of cerebral edema into 
cytotoxic and vasogenic118 is important. Whereas the clinical response to steroids of the 
cytotoxic edema type is uncertain, BBB damage with pathologically separated tight 
junctions, as well as with disturbed pinocytosis (as seen in brain tumors) is highly 
responsive. In a study comparing dexamethasone and a dexamethasone+mannitol 
combination with placebo,130 no effect on ten-day survival rate occurred. In a recent 
review,131 glucocorticoids were considered ineffective in treatment of ischemic edema, 
and Cochrane analysis does not support their use in ischemic stroke.132 
 
However, most conducted trials included few patients and started treatment too late; of 
22 published trials, only 7 were accepted for Cochrane analysis. Besides having 
inadequate numbers of patients, these trials had no uniformity of evaluation or 
assessment, and reached disparate conclusions. Still, some authors justify the use of 
steroids,133 and around 20% of US or Chinese physicians routinely use corticosteroids for 
ischemic stroke patients.132 
 
Steroids do, however, raise risk for infections, hyperglycemia, and muscle catabolism, 
and it is debated whether the widespread use of steroids in response to a marginal 
therapeutic gain would expose large numbers of stroke patients to the more serious 
hazard of steroid treatment and convert patients who would otherwise have died into 
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bedridden, miserable survivors; the majority would consider this worse than death. Some 
authors134 thus propose that no large multicenter trial is justified. 
 
Barbiturate coma reduced the increase in ICP, but seemed to have no positive effect on 
neurologic outcome.135 That study included no control group, however, and was tested 
only after failure of osmotherapy and hyperventilation. Indomethacin has achieved 
short-term ICP reduction, but a continuous infusion was ineffective.136 
 
Regarding more recent strategies, hypothermia reduces cerebral metabolic rate, BBB 
disruption, edema formation, free radical formation, release of excitatory aminoacids, 
inflammatory response, and apoptosis, and, importantly, improves clinical outcome.46 
Invasive decompressive craniectomy (< 48 hours) is recommended as the treatment of 
choice for patients aged 60 years or younger—with severe infarction of at least 50% of 
the MCA territory—reducing mortality and improving outcome.137 However, with this 
approach, the chance of surviving in a condition requiring assistance from others 
increases >10 times. 
 
Experimentally, besides these clinical strategies, an enormous number of other agents 
and approaches have been tested with promising results. These include albumin138 
(acting presumably by diminishing bulk flow through the disrupted BBB and ameliorating 
vasogenic edema), bradykinin receptor antagonists,139 and arginin vasopressin receptor 
antagonists.140 Furthermore, aquaporin-4 deletion,141 tumor necrosis factor (TNF)-α 
neutralization,142 interleukin (IL)-1 receptor antagonists,143 MMP inhibition,144 ET-A 
receptor antagonists,145 free radical scavenging,146 and many others to some degree 
help. Interestingly, the TPA inhibitor neuroserpin reduced ischemic edema in TPA-treated 
rats.147,148 
 
2.1.3.2 Hemorrhage 
The etiology of post-thrombolytic hemorrhage after TPA is not understood. However, the 
mechanisms that mediate hemorrhagic transformation are likely to be correlated with 
components of RI, especially the BBB and basal lamina disruption.83 Several suggested 
triggers include oxidative stress and oxidative damage to membranes constituting the 
BBB, matrix proteolysis, and vascular response (section 2.1.3). 
 
VEGF expression is induced by focal cerebral ischemia, and iv VEGF application 
significantly increases BBB disruption, hemorrhage, and lesion volumes in rats subjected 
to ischemia.149 An interesting approach to ameliorate endothelium damage and TPA-
associated hemorrhage was reported by the group of Eng Lo.150 In that study, 
immunoliposomes, recognizing intracellular antigens (anticytoskeletal antiactin) exposed 
in ECs after membrane damage, were used to bind to and “reseal” the damaged 
membrane. Endothelium can be directly injured by ROS,151 and this detrimental effect is 
blocked by antioxidants.152 Moreover, free radical spin traps have reduced experimentally 
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both spontaneous hemorrhage and thrombolysis-mediated hemorrhage,153,154 improving 
outcome. 
 
Confirming the overlapping pattern of pathways involved in hemorrhagic 
transformation, ROS production is highly correlated with focal areas of gelatinase activity 
in microvessels within the ischemic mouse brain.144 Gelatinases, in turn, can degrade 
constituents of the basal lamina, enhancing vascular permeability and erythrocyte 
extravasation with consequent hemorrhage. Studies from the del Zoppo group71,84 show 
that loss of integrity of basal lamina constituents and its connection with surrounding 
structures leading to BBB disruption is associated with hemorrhagic transformation. 
 
Extracellular proteolysis includes activity of the serine proteases, PAs, MMPs, and 
proteases secreted by activated PMNL. Plasmin, activated by TPA or urokinase type PA, 
activates MMP-9 and MMP-2.155 Activation of MMPs contributes to the dissolution of the 
basal lamina and correlates with development of hemorrhage.71,91 TPA-induced 
hemorrhage, in turn, is significantly reduced by MMP inhibition,92,156 as is TPA-mediated 
mortality157 in experimental ischemia-reperfusion. 
 
PAs contribute to ECM degradation,158 acting by plasmin generation or activation of 
MMPs. Plasmin augments capillary injury by acting with other proteolytic enzymes to 
disrupt the ECM, contributes to the activation of the membrane-type metalloproteinase 
involved in activating gelatinase A (MMP-2), and activates ECM-degrading enzyme 
stromelysin.159 Furthermore, plasmin can activate MMP-1 and MMP-3, whereas plasmin 
inhibitors as well as antibodies to urokinase type PA inhibit activation of pro-MMP-2.93,160 
 
There exists some body of clinical evidence showing that MMPs are involved in 
hemorrhagic transformation with or without thrombolysis,161-163 with one study showing a 
clear correlation between pretreatment levels of MMP-9 and intracranial hemorrhagic 
complications.163 Besides showing increased levels of MMP-2 and MMP-9, and, 
importantly, also significantly decreased levels of intact laminin and TIMP-2, the study by 
Horstman and coworkers162 was the only one that analyzed the activity of MMPs. In that 
study, the active form of MMP-9 appeared in only 4 of 17 patients treated with TPA but in 
no patients receiving heparin or undergoing hypothermia. 
 
Since most experimental and clinical studies report latent but not active forms of MMP-2 
and MMP-9 as appearing after MCA occlusion, their role in matrix degradation was in 
question.86 As one answer, a role for the cysteine proteases cathepsins B and L in 
degradation of the matrix component perlecan as early as 2 hours after MCA occlusion 
emerged experimentally.86 
 
Apart from spin trap agents and MMP inhibitors, the glycoprotein IIb/IIIa platelet 
receptor antagonist reduces hemorrhage when coadmistrated with thrombolysis,164 
presumably influencing vessel reocclusion and the ”no-reflow” phenomenon. 
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2.1.3.3 Neutrophil infiltration and inflammatory response 
Under normal conditions, the cerebral microvascular endothelium acts as a barrier to the 
immune system that limits the entry of neutrophils and other leukocytes into brain 
tissue. Neutrophils can be detected in the microvessels of the ischemic hemisphere as 
early as 30 minutes after the arterial occlusion, peaking at 12 hours.165 They are the first 
inflammatory cells to arrive in the ischemic tissue between 1 to 6 hours after 
reperfusion,101,165,166 peaking at 24 hours and still visible after 7 days.165 In the clinical 
scenario, neutrophil counts peaks at 1 to 3 days postinfarction.167 Neutrophils are 
believed to contribute to the secondary damage by causing capillary plugging, 
microvascular disruption, edema, and hemorrhage. This process involves cytokines, lipid-
derived mediators, proteases, and free radicals.168 
 
Circulating monocytes can be detected within the microvasculature of the ischemic 
hemisphere after 4 to 6 hours.165 Experimentally, macrophages become the predominant 
cell type within a few days,101 and clinically within 1 to 2 weeks of neutrophil 
infiltration.167 Interestingly, experiments with bone marrow chimeric mice during 
transient focal cerebral ischemia suggest that resident microglial activation precedes 
macrophage infiltration, and that the vast majority of macrophages in the infarcted area 
are derived by differentiation from local microglia.169 
 
Microvascular obstruction by platelets, fibrin, and neutrophils (the “no-reflow” 
phenomenon) can worsen the degree of ischemia,70,170-172 and production of toxic 
mediators by activated inflammatory cells and injured neurons (cytokines, NO, 
superoxide, and prostanoids) can amplify tissue damage. Neutrophils may contribute to 
further disruption of the endothelium and the BBB by producing free oxygen radicals and 
proteolytic enzymes; infiltrating neutrophils release an active form of MMP-9.173 Protease 
activity resulting from leukocytes binding to activated endothelium may lead to 
degradation of cadherin (Figure 2), a component of the endothelial cell-to-cell junction.174 
Furthermore, increased leukocyte migration alters the molecular organization of the tight 
junction complex, the reorganization of the actin cytoskeleton, and the BBB disruption.175 
 
The precise role of neutrophils in ischemia-reperfusion is still debated. Some authors 
consider neutrophils to have nothing but a bystander’s role in the ischemia-reperfusion 
scenario,166,176,177 while others suggest a critical causative role for them.178,179 Several 
lines of evidence support the latter view. First, correlation exists between the time course 
of neutrophil accumulation in the ischemic zone and the expansion of cerebral damage 
during reperfusion in rats,180,181 in nonhuman primates,70,182 and in humans.183 Second, 
the beneficial effect of neutropenia on RI in experimental settings184,185 and the 
deleterious effect of elevated neutrophil count on stroke outcome in humans186 is known. 
The last line of evidence comes from works studying adhesion molecules and recruitment 
of neutrophils during reperfusion as well as from the effect of anti-adhesion therapeutic 
strategies. 
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The adhesion of neutrophils to the endothelium follows initial contact and rolling; 
thereafter, transmigration into the cerebral compartment takes place. The recruitment 
process involves interactions between three groups of adhesion molecules: selectins, the 
immunoglobulin gene superfamily, and integrins.66,187 E-selectins occur in ECs, L-
selectins in leukocytes, and P-selectins in both platelets and ECs; all of these are 
involved in the low–affinity rolling of the neutrophil to the endothelium.66 The high-
affinity binding involves the immunoglobulin gene superfamily members together with 
their ligands, which are members of the integrin family.66,187 The immunoglobulin gene 
superfamily members are expressed in ECs, including intercellular adhesion molecule 
(ICAM)-1 and -2, vascular cell adhesion molecule-1 (CD106), platelet-endothelial cell 
adhesion molecule-1, and mucosal addressin.188 Integrins, in turn, are expressed in the 
circulating neutrophils and not only participate in binding of the neutrophils to ECs, but 
also mediate their adhesion to the ECM components fibronectin and laminin.188,189 The 
most common integrins share a subunit β2, αMβ2 (recognizes ICAM-1), αLβ2 (interacts 
with ICAM-1 and -2),190 or subunit β1.191 
 
Studies with adhesion molecules in the experimental192,193 and clinical167 setting showed 
different mediators to be involved in the upregulation of the adhesion molecules during 
experimental cerebral ischemia-reperfusion in vivo or in vitro. Specifically, TNF-α and IL-
1 influence the expression of selectins194 and ICAM-1.195 Furthermore, platelet-activating 
factor (PAF) upregulates integrins on neutrophils.196 Therapeutic antiadhesive approaches 
lead to amelioration of inflammatory response after transient ischemia in rats197,198 and 
nonhuman primates.171 In addition, Bowes and coworkers199 found treatment with the 
anti-ICAM-1 antibody to lengthen the therapeutic window for beneficial administration of 
TPA. Antiadhesive strategies, however, show no beneficial effect in models of permanent 
ischemia.200 
 
Despite promising results from anti-inflammatory strategy in experimental stroke, 
clinical trials with a murine anti-human ICAM-1 antibody (enlimomab) and inhibition of 
neutrophils were negative.201,202 To define the possible mechanism of this negative result 
in the enlimomab trial, Furuya and coworkers203 treated rats with a murine anti-rat 
ICAM-1 antibody and reported production of host antibodies against the heterologous 
protein administered and activation of circulating neutrophils, complement, and 
microvasculature. 
 
Furthermore, the nonhumanized murine IgG2a subtype antibody itself activates 
complement in human whole blood, which leads to inflammatory consequences such as 
increased expression of CD11b/CD18 adhesion molecules and radical production of 
neutrophils.204 These responses may be responsible for the failure of the clinical 
enlimomab trial as well as for the body-temperature elevation and the excess of cerebral 
causes of death in that trial.202 
 
Although, in their review, Emerich and coworkers,166 who claim the bystander’s role for 
neutrophils, found no clear cause-effect relationship between leukocyte recruitment and 
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the pathogenesis of ischemia, they call for additional experiments to shed light on this 
subject. 
 
2.1.4 Models of focal cerebral ischemia 
 
The clinical variability of stroke (causes, localization, duration, severity, and coexisting 
systemic diseases) requires large patient cohorts in clinical trials in order to avoid 
confounding effects of this diversity. Thus, experimental models serve as a tool of 
investigation under strictly controlled conditions, and can provide us with important and 
clinically relevant data concerning mechanisms of ischemic cerebral injury and 
development of novel drugs. 
 
In general, the ideal animal model should be relevant to the clinical situation, be 
reproducible, have minor or no extracerebral side-effects, and be technically easy to 
perform. It is obvious that no single animal model simulates all aspects of ischemic 
stroke, since it is a heterogeneous, incidental condition that occurs spontaneously, often 
triggered, if not governed, by profound precipitating factors such as infection, trauma or 
serious other comorbidity. 
 
It should be mentioned that the relevance of stroke models to human stroke has been 
debated, since many assumed neuroprotective compounds fail to show efficacy in 
humans, despite positive results in preclinical settings.205,206 On the other hand, ischemic 
stroke models contribute largely to understanding of pathophysiologic mechanisms, e.g., 
excitotoxicity, free radical generation, RI, periinfarct depolarizations, inflammation, BBB 
injury, programmed cell death, and gene expression after ischemia. Furthermore, these 
models play a significant role in developing methods for investigating the brain; a good 
example is the development of novel MRI modalities such as perfusion- and diffusion-WI, 
which were tested in rodent models in the 1990’s and were rapidly incorporated into 
clinical practice.207 Once we identify all possible causes of unsuccessful translation of the 
positive experimental neuroprotective studies into clinical practice, it is more likely that 
diverse effective treatments for ischemic stroke will soon be revealed. 
 
The rat is the animal most commonly used for studying cerebral ischemia, although 
larger animal species (cats, dogs, rabbits, and nonhuman primates) have also been used. 
What makes rodent models dominant is their low cost, easy transportation, storage, and 
feeding, relative homogeneity within strains (inbreeding), and resemblance of their 
cerebrovascular anatomy208 and physiology to that of higher species. Small brain size is 
suitable for fixation procedures, for microscopic and macroscopic examination, and for 
biochemical analysis. It is easy to perform physiological monitoring and to replicate 
studies, with greater acceptability from ethical perspectives. 
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The anatomic distribution of the anterior cerebral artery (ACA), posterior cerebral artery 
(PCA), and the MCA in rats is analogous to that in humans.208 Although in rats the PCA 
arises from the proximal intracranial portion of the internal carotid artery (ICA), the 
posterior communicating artery connects the terminal cerebellar branch of the basilar 
artery with the PCA. The blood supply to the rat thalamus and basal ganglia is also 
similar to that in humans.209 Most stroke models are based on inducing ischemia in MCA 
territory to mimic a common clinical situation. Extracranial occlusion of a carotid or 
vertebral artery without further surgical intervention does not produce cerebral ischemia 
in the rat (except in spontaneously hypertensive rats) because the circle of Willis 
provides sufficient collateral blood supply via the nonaffected vessels. 
 
2.1.4.1 Craniectomy-requiring early MCAO models 
These models are quite invasive, expose the brain to the atmosphere, affect ICP and BBB 
function, and do not produce large and reproducible infarcts.210 Robinson and 
coworkers211 first described ligation of the distal portion of the MCA in rats, which did not 
provide reproducible infarcts and cause no striatal damage. Others208 accessed the more 
proximal regions of the MCA via a subtemporal approach, which produced an infarct 
involving both the cortex and the striatum. This model was modified by using a ligature 
or a clip to occlude the MCA for achieving reperfusion, but inconsistent patterns of 
reperfusion occurred.208 
 
2.1.4.2 Intraluminal suture MCAO model 
The most popular experimental model to induce focal cerebral ischemia is the suture 
occlusion model of the MCA, first described by Koizumi and coworkers,212 who used a 4-0 
nylon monofilament occluder with its tip rounded near a flame and then coated with 
silicon. They permanently occluded the common carotid artery (CCA) and the external 
carotid artery (ECA). The monofilament was inserted through an arteriectomy of the 
ipsilateral CCA and moved forward approximately 17 mm beyond the carotid bifurcation 
into the ICA and upwards, occluding the origins of the ACA, MCA, and the posterior 
communicating artery. This model allows large, well-reproducible infarcts because the 
coated suture completely obstructs the MCA trunk and the major sources of collateral 
blood flow. Zea Longa and coworkers213 developed a similar model in which they inserted 
a 4-0 monofilament suture (without silicon coating) through the ECA while keeping the 
ipsilateral CCA patent. The infarct sizes produced with the Zea Longa’s model are 
smaller, with larger variability because of a higher and more variable residual blood flow 
into the ischemic regions.214 
 
Both models allow reperfusion, and do not require extensive surgery. The infarcts in 
suture models include cortical, subcortical, and hippocampal portions having a large 
penumbra, which makes these models preferable for drug-efficacy studies. Furthermore, 
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the time of reperfusion can be successfully controlled by withdrawal of a suture at 
desired intervals, making it practical for studies of RI. The high mortality rate limits, 
however, long-term observation studies with these two models. The length of the 
inserted filament required for a successful MCAO depends on several factors including 
body weight, rat strain, and vendor. Required filament length ranged from 17 to 22 mm 
among studies.212,213,215 
 
2.1.4.3 Thromboembolic models of the MCA 
This model simulates human stroke reasonably well and allows for study of both 
thrombolytic therapies and neuroprotectives. In the older thromboembolic models,216 a 
suspension of small thrombi was injected into the ICA while blood circulation was being 
allowed through the CCA. The thrombi usually lodged in small arteries in the MCA 
territory causing multiple small lesions not particularly relevant for human disease. 
Furthermore, early spontaneous recanalization was a disadvantage of this model. Later, a 
single macroclot (fibrin-rich embolus) was used for MCA trunk or major branch 
occlusion.217 Even if this model closely mimics human stroke, it causes a large variation 
in infarct size due to differences in the exact sites of occlusion. Its low reproducibility 
hampers its general use. Recently, Busch and coworkers218 reported considerable 
improvement by injecting multiple fibrin-rich clots into the ECA one after another; this 
led to a consistent reduction in CBF without spontaneous reperfusion within 3 hours after 
emboli injection. 
 
2.1.4.4 Other, non-clot, embolic models 
Different artificial embolic materials have served to induce ischemia. The lesion 
development is slow, increasing in size up to 24 hours postinjection. Microsphere model 
may provide a larger therapeutic window for drug testing in stroke, but the lesions are of 
a multifocal and heterogeneous nature.219 
 
2.1.4.5 Photochemically induced focal ischemia 
This relatively noninvasive model is not widely used. It involves systemic administration 
of the photosensitive dye rose bengal, and irradiation of specific areas of the brain with a 
focused light beam at a specific wavelength. A reaction between the light and the 
circulating dye generates free radicals, resulting in platelet aggregation and 
thrombosis.220 Lesion site and size can be selected by the researcher. Lesion size and 
depth depend upon intensity of the irradiating beam, duration of irradiation, and dose of 
rose bengal. The typical infarct is a sharply circumscribed, bowl-shaped necrotic lesion 
occupying the full cortical thickness but sparing underlying structures. Early BBB 
breakdown and vasogenic edema give rise to progressive microvascular compression at 
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the lesion periphery. The main disadvantage is the absence of a penumbra region around 
the ischemic core; there is, instead, a ring of hyperperfusion.221 However, model 
improvements seem to induce cortical ischemic lesions involving a penumbra-like 
lesion.222 Another disadvantage of this model is the end-arterial occlusive character of 
the lesion, which makes it resistant to collateral-perfusion-enhancing approaches. Still, 
this model can aid in testing drugs for restorative function and evaluation of neuronal 
repair. 
 
2.1.4.6 Endothelin-1-injection model 
A restriction associated with current models of MCAO is the mechanical damage caused 
to the vessel by clip or occluder. A novel method of MCAO is infusion of ET-1 directly onto 
the exposed MCA223 or adjacent to the MCA by stereotaxic injection.224 Such an ET-1 
infusion produces a dose-dependent narrowing/occlusion of the MCA. Although this model 
is less invasive and enables production of ischemia in a desired brain region, the dose-
dependent action of ET-1 still reduces control of ischemia: of its severity and duration. 
 
2.1.4.7 In-bore MCAO models for MRI studies 
Since the time that MRI became a powerful and widely available tool for studying 
hyperacute brain ischemia, developing models to induce focal ischemia and reperfusion in 
the MRI scanner has become a necessity. This allows for collection of pre- and post-
ischemic images that are spatially co-registered and later, comparison of preischemic 
findings to ischemic changes. Such in-bore occlusion models may be as successful as the 
classical MCAO models.215 
 
2.1.4.8. Summary of the ischemic stroke models 
To sum up, the thromboembolic model is most relevant to human stroke, but its 
disadvantage is varying rate of spontaneous recanalization (making controlled 
reperfusion impossible) and a higher variability in lesion volumes. Suture MCAO is easy 
to perform, allows absolute control over reperfusion, and makes lesion volumes more 
reproducible. Its disadvantages include: a risk for subarachnoid hemorrhage (SAH), 
higher mortality in long-term experiments, and hyperthermia in permanent ischemia. 
Although the craniectomy models allow control of the site of occlusion (thus the infarct 
size and mortality), they are rather invasive and depend on the surgeon’s skills. The 
photothrombotic model is less invasive and allows induction of the lesion in the desired 
cortical region. However, this model is less relevant to human conditions, since it 
typically lacks the penumbral tissue zone. Application of ET-1 to different brain regions 
controls lesion location and volume, but offers only modest control over ischemia 
duration and intensity. 
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2.2 Intracerebral hemorrhage 
 
ICH is caused by bleeding into the brain parenchyma. In Western countries, ICH accounts 
for 15% of all cases of stroke, and the rate is even higher (20-30%) in Asian and African 
populations.6 Nontraumatic ICH can be divided into one type that arises from pre-
existing macroscopic “ictohemorrhagic” vascular lesions (secondary ICH) and one that 
does not (primary ICH).225 The former includes arteriovenous malformations, cavernous 
malformations, aneurysms, brain tumors, and dural fistulas; the latter, accounting for 
approximately 85% of all cases,226 is caused by micro-aneurysm-associated (Charcot 
Bouchard aneurysms) hypertension and amyloid angiopathy.225 Other rare conditions 
include cerebral venous thrombosis, cerebral endometriosis, convulsions, and pregnancy 
toxemia. 
 
Arterial hypertension is the most important risk factor for a nontraumatic primary ICH, 
present in approximately 50 to 70% of such patients.226 Even borderline isolated 
hypertension is associated with increased risk for ICH.227 Other factors include excessive 
use of alcohol, smoking, serum cholesterol levels less than 4.1 mmol/l (although a less 
reliable factor), and the presence of ε2 and ε4 alleles of the apolipoprotein E gene as 
related to amyloid angiopathy-associated ICH. Deficiencies in coagulation factors I, VII, 
VIII, IX, XIII, and von Willebrand factor are associated with ICH, as well. In addition, 
advanced age, male gender, pregnancy, the delivery and postpartum period, African or 
Japanese race, and use of anticoagulants, antiplatelet drugs, and cocaine also play a 
role.226,228 
 
Physicians treating ICH patients possess no tool comparable to TPA in ischemic stroke. 
On the contrary, hemostatic therapy, considered the counterpart to emergency TPA 
treatment, was not found beneficial (see below). Currently, no widely approved effective 
acute medical treatment exists, and surgical evaluation of ICH was recently found not to 
be beneficial.14 
 
Thus, ICH is associated with high mortality and disability, with 60 to 70% of the patients 
surviving through the first month and only 40 to 50% through the first year,7,8 many of 
them with chronic disability. An even worse (95%) 3-month mortality is associated with 
those patients having large, deep hemorrhages associated with coma.228 Poor outcome 
results from direct tissue damage, especially in deep brain structures (associated with 
disruption of the internal capsule) and the mass effect of the growing hematoma and 
edema. These factors contribute to expansive brain swelling and lead to displacement 
and disruption of brain structures and often to increased ICP. 
 
While white matter and cortical hemorrhages are more likely due to amyloid angiopathy, 
arterial hypertension is usually deemed the underlying cause of ICH in areas that are 
supplied by the vessels arising from the high pressure of the circle of Willis (Figure 3), 
leading to hemorrhages in the basal ganglia (35-44% of cases), thalamus (10-25%), 
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cerebellum (5-10%), pons (5-9%), and neocortex (19-25%).6,228. Accordingly, ICH can 
be divided into supratentorial and posterior fossa hemorrhages. 
 
Figure 3. Common sites of intracerebral hemorrhage. A) 
Cerebral lobes - originating from penetrating cortical 
branches of the anterior, middle, or posterior cerebral 
arteries. B) Basal ganglia - originating from ascending 
lenticulostriate branches of the middle cerebral artery. C) 
Thalamus - originating from ascending thalamogeniculate 
branches of the posterior cerebral artery. D) Pons - 
originating from paramedian branches of the basilar artery. 
E) Cerebellum - originating from penetrating branches of the 
posterior inferior, anterior inferior, or superior cerebellar 
arteries. Reproduced from Qureshi A et al. N Engl J Med 
2001; 344:1450-1460 with the written permission of the 
copyright holders. 
 
2.2.1 Pathophysiology of intracerebral hemorrhage 
 
Nontraumatic intraparenchymal hemorrhage without pre-existing ictohemorrhagic 
vascular lesions arises from the rupture of the small penetrating arteries that originate in 
the ACA, MCA, PCA, and in the basilar artery, all affected by degenerative changes 
associated with  hypertensive arteriolosclerosis or amyloid angiopathy. Following 
the hemorrhagic event, direct tissue destruction and dissection of blood along tissue 
planes occurs, followed by edema formation and ICP increase. Delayed damage can be 
mediated by toxins associated with blood breakdown products, thrombin, and leukocyte 
infiltration. The role of secondary ischemia after ICH has been a subject of debate. 
 
2.2.1.1 Hematoma growth 
ICH is not a single-bleed event that stops quickly once it has started. In a prospective 
study,229 early hematoma growth occurred in 38% of 103 patients within 20 hours 
after baseline imaging (scanned primarily within 3 hours of symptom onset), with two-
thirds of the patients already showing hematoma growth 1 hour following baseline 
imaging. Hematoma expansion is suggested to arise from continuous bleeding from the 
primary source and from the mechanical disruption of surrounding vessels,230 with acute 
hypertension and a local coagulation deficit possibly contributing to the expansion.231,232 
 
Hematoma growth is an important predictor of outcome after primary ICH,233 and its 
clinical importance is supported by a recent meta-analysis.234 The mass effect of the 
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growing hematoma may result in increased ICP, transtentorial herniation, and dramatic 
reduction in CBF. In addition to the mass effect, the hematoma itself induces a number 
of secondary changes in the surrounding tissue, including neuronal and glial cell death 
due to necrosis and apoptosis,9-11 inflammation (see below), and vasogenic edema 
caused by disruption of the BBB.12,13 
 
2.2.1.2. Is there a perihematomal penumbra? 
The mass effect of the ICH is thought to induce secondary ischemic injury due to direct 
mechanical compression of the blood vessels surrounding the hematoma and 
vasoconstrictor substances in blood; to this end, the term “perihematomal penumbra” 
was proposed based on a number of experimental studies in rats235-237 and in primates,238 
as well as in clinical studies.239,240 
 
Debate is ongoing, however, as to whether such a perihematomal penumbra exists. No 
evidence of perihematomal ischemia was found by other researchers in 
experimental241,242 and clinical studies using MRI.243-245 Butcher and coworkers245 
reported self-limited perihematomal oligemia, which normalized 3 to 5 days after 
symptom onset, and reported that the relative apparent diffusion coefficient (ADC) (ratio 
of ADC perihematomal / contralateral homologous regions) independently predicted 
absolute and relative edema volume, demonstrating its correlation with the rate of 
diffusion. This is the case for edema derived from extravasated plasma, but not acute 
ischemia-associated cytotoxic edema. 
 
MRI-based results may, however, be misleading, since perihematomal measurement of 
diffusion may be influenced both by reduced ADC due to ischemia-related cytotoxic 
edema and, conversely, by increased ADC due to hemorrhage-related extracellular 
vasogenic edema.246 Moreover, hemoglobin and its degradation products may interfere 
with analysis of MRI data.246 
 
To continue the debate, PET studies (analyzing CMRO2, OEF, and CBF) produced findings 
not consistent with ischemia and showed preserved autoregulation. This suggests that 
hypoperfusion surrounding ICH reflects reduced metabolic rate rather than ischemia.247-
249 Similarly, Herweh and coworkers250 found in a human perfusion CT study no evidence 
of perihematomal penumbra. Diaschisis (remote autoregulatory hypoperfusion due to 
reduced oxygen demand), caused by inflammatory tissue damage and mass effect of the 
growing hematoma and clot-related vasogenic edema, is a probable reason for the 
commonly observed perihematomal perfusion alterations, as suggested earlier by the 
same group.243 
 
In addition, Sook Kim-Han and coworkers251 recently reported mitochondrial impairment 
and not ischemia to be responsible for the reduced metabolic demand. However, Nilsson 
and coworkers252 found in a human study a perihematomal penumbra zone with 
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biochemical characteristics similar to that of the penumbra surrounding traumatic brain 
contusions. Such penumbra shows a relatively rapid (24–48 hours) normalization after 
surgical evacuation of the hematoma. Still, the changes observed in traumatic brain 
injury patients are suggested to be of mitochondrial dysfunction origin rather than being 
ischemia,251 as supported by some others.253 Furthermore, ROS produced by impaired 
mitochondria are likely to play a role in a progressive decline in mitochondrial respiration, 
and interact with metals released from the blood, which leads to oxidative damage.251 
 
Because it seems that ischemia does not play a considerable role in the pathogenesis of 
perihematomal tissue damage, other mechanisms are proposed to play a role. These 
include excitotoxicity,13,254 inflammatory changes with activation of leukocytes and 
platelets leading to production of inflammatory mediators (IL-1, IL-6, ICAM, TNF-α, and 
VEGF),254-257 and involvement of complement258 and MMPs.12,259 In addition, a role for 
thrombin, fibrinogen, TPA,12,260,261 and clotting factors262 together with blood degradation 
products263 has been proposed. Studies in humans support the role of cytokines (IL-6 
and TNF-α)254,257,264 and MMPs (especially MMP-3, MMP-9, and presumably MMP-
12)254,265,266 in the pathophysiology of ICH. Last but not least, hyperglycemia exacerbates 
perihematomal cell death and brain edema.267 
 
2.2.1.3 ICH-induced edema 
Gebel and coworkers268 found absolute edema to increase by 37% from baseline to a 1-
hour CT scan and to double during the first 24 hours, whereas relative edema (absolute 
edema volume divided by hematoma volume) increased by 75% during the first 24 
hours. Relative edema, representing vasogenic edema (shown as increased relative 
ADC), is associated with outcome in some233 but not in all243 human studies. Such 
elevation of perihematomal ADC is significantly associated with hematoma volume.269 
Importantly, only a minimal association exists between relative edema volume and 
hematoma volume, confirming that hematoma volume does not confound relative edema 
volume measurement.268 
 
Several studies address the role of the blood together with its degradation products 
and the coagulation cascade in association with ICH-induced brain edema. Contact 
between blood and tissue factor activates the extrinsic coagulation system,270 leads to 
thrombin formation, and converts the blood into coagulum. Tissue factor was found in 
the cortex, basal ganglia, cerebellum, and cervical spinal cord of the baboon.271 Lee and 
coworkers272 studied the role of thrombin by injecting various solutions into the basal 
ganglia of rats. Evaluated 24 hours after injection, only whole blood but neither 
concentrated blood cells, nor serum from clotted blood, nor plasma from unclotted blood 
induced brain edema. However, adding prothrombinase to plasma led to edema 
formation similar to whole blood-mediated one; hirudin (a thrombin inhibitor) reduced it. 
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In further experiments, the same group found that infusion of packed erythrocytes led to 
delayed edema formation 72 hours later, whereas infusion of already lysed erythrocytes 
led to edema formation within 24 hours.242 The latter finding suggests hemoglobin 
involvement. The role of thrombin and the coagulation cascade was studied in another 
study by the same group273 when they injected blood, artificial clot (composed of styrene 
microspheres, fibrinogen, and thrombin), and separately the components of the artificial 
clot. Early edema was formed after clotting of the hematoma by exudation of the 
remaining serum proteins into the periphery of the hematoma.258,268,274 Such hyperacute 
perihematomal edema was reduced by intrahematomal administration of TPA and 
prevented by an intrahematomal heparin injection.275 
 
Based on extensive studies, the temporal evolution of experimental perihematomal 
edema has been described.226,276 Hyperacute edema (< 24 hours) seems to be caused 
oncotically by serum proteins, glucose, and electrolytes. Acute edema (24-72 hours) may 
be caused by cellular toxicity (white blood cells and platelets), humoral toxicity (IL-1, IL-
6, ICAM, TNF-α, prostaglandins (PG), LTs, VEGF, and complement), the coagulation 
cascade (thrombin, fibrinogen, and TPA), and excitotoxicity (glutamate). Finally, the late 
phase (> 72 hours) is suggested to involve blood degradation products (hemoglobin, 
iron, and biliverdin), NO, free radicals, apoptosis, and MMPs. 
 
The BBB, the target of the various pathways leading to its disruption, seems to remain 
intact against large molecules for the first several hours,274 with modest disruption at 12 
and 24, but progressive disruption 48 hours later.277 In our laboratory, we observed no 
BBB disruption, as judged by Evans blue (EB) albumin extravasation at 24 hours after 
ICH (unpublished data). Concordantly, Xi and coworkers242 reported BBB disruption only 
72 hours after packed erythrocyte injection, but only 24 hours after lysed erythrocyte 
infusion. 
 
Differing experimental approaches to counteract the ICH-induced edema include MMP 
inhibitors,87 inhibitors of monocytes/microglial activation leading to decrease in released 
cytokine levels,278 inhibitors of complement activation,258 NMDA-antagonists,279,280 
antioxidants,281 erythropoietin,282 and albumin.283 Thrombin preconditioning reduces 
edema caused by erythrocytes and free iron.284 Argatroban, an inhibitor of both fibrin-
bound and free thrombin, reduces brain edema after ICH, presumably by interfering with 
thrombin-induced inflammatory responses.285 
 
2.2.1.4 Inflammatory responses 
After the hemorrhagic event, extracellular spaces of the brain are exposed to many blood 
components (hemoglobin, thrombin, plasmin, complement, fibrin degradation products, 
and leukocytes), which induce inflammatory responses.255,276,286  Iron and iron-related 
compounds, including hemoglobin, catalyze hydroxyl radical production and lipid 
peroxidation, causing oxidative stress to the brain cells.287 Interestingly, the only clinical 
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study addressing the role of free radicals in ICH288 found no difference between ICH and 
control patients. However, the control tissue originated from peritumor and aneurysmal 
tissue, which may not represent an appropriate control.255 
 
Clotting blood and damaged brain tissue liberate chemotactic factors, including thrombin, 
which is suggested to potentiate neutrophil infiltration.289,290 Neutrophils, in turn, may 
contribute to the secondary tissue injury via processes involving the release of ROS, 
proteases,289,291 and cytokines such as TNF-α and IL-6.292 Although the primary role for 
activated microglia/macrophages after ICH is to clear the hematoma and tissue debris, 
they may contribute to further tissue damage12 through release of cytokines, ROS, and 
NO.11,255 
 
However, despite the increasing amount of evidence concerning the role of inflammatory 
machinery after ICH, what remains to be proven is whether the inflammation following 
ICH contributes directly to neuronal loss or is it merely an epiphenomenon. Some 
experimental data suggest a direct contribution based on the effects of various anti-
inflammatory therapies. 
 
To this end, different strategies were tested including antibodies against adhesion 
molecules,197 anti-inflammatory actions of atorvastatin (decreased inducible NO-synthase 
expression and leukocytes and microglia infiltration),293 cyclooxygenase-2 inhibitors,294 
targeting of microglial activation by minocycline12 or tuftsin fragment 1-3,278 MMP 
inhibitors,259,295 overexpression of IL-1 receptor antagonist,296 inhibition of TNF-α,256 
adenosine A2A receptor activation (presumably also by inhibition of TNF-α mRNA 
expression),297 heme oxygenases,281 deferoxamine,298 and free radical trapping.255,299 A 
clinical trial that primarily addressed the safety of the free radical-trapping agent NXY-
059 in ICH patients found no benefit nor harm in terms of the 3-month functional 
outcome,300 despite the positive results of an experimental study.299 
 
2.2.2 Surgery or medical treatment for intracerebral hemorrhage? 
 
Despite considerable efforts to dissect the pathophysiology of ICH, no other than 
supportive and symptomatic treatment modalities exist. These include proper control of 
the airways, breathing, and of circulation, blood pressure management, ICP monitoring, 
fluid balance, fever control, nutritional support, prophylaxis of gastrointestinal 
complications, seizures, and deep venous thrombosis. 
 
2.2.2.1 Surgery 
The rationale for surgical treatment in ICH is removal of the cause of the mass effect and 
reduction in toxic effects of the breakdown products of blood components. However, 
    
42 
surgical treatment of ICH failed to prove beneficial in a recent Surgical Trial in 
Intracerebral Hemorrhage (STICH).14 
 
Unfortunately, the STICH trial did not differentiate basal ganglia-located ICH associated 
with intraventricular hemorrhage and hydrocephalus from superficially-located lobar ICH, 
which shows better prognosis.301 Another unfortunate aspect of the STICH trial was the 
patients’ randomization according to the neurosurgeon’s subjective consideration of the 
need for surgical intervention either initially or during the immediate follow-up. This 
resulted in randomization of only 221 patients with lobar ICH (out of total 1033 patients), 
because many neurosurgeons favor surgery for these patients despite the absence of 
meaningful evidence for such a decision. Lack of any evidence was actually the reason to 
start the STICH trial. The pre-specified subgroup analysis of this trial found a 29% 
relative benefit for early surgery in patients with the more superficial ICH reaching 
subcortically within 1 cm of the cortical surface14; such subgroup analysis would, if 
corrected for the pre-specified subgroups, miss statistical significance. 
 
An ongoing STICH II trial will address the outcome of early surgery in lobar 
nonaneurysmal ICH (reaching to within 1 cm of the cortical surface) without 
intraventricular hemorrhage.302 The European Stroke Initiative recommends surgery for 
superficial hematomas in the latest guideline303; falling CCP and rising ICP together with 
deteriorating consciousness level are also indications for surgical evacuation.301 Other 
ongoing ICH trials address treatment of intraventricular hemorrhage with clot volume 
smaller then 30 ml (CLEAR IVH)304 and minimal invasive surgery in deep ICH 
(MISTIE).305 
 
2.2.2.2 Recombinant Factor VII 
Due to early hematoma growth, hemostatic therapy in ICH was considered to be a 
counterpart of emergency TPA treatment for acute ischemic stroke. To this point, ε-
aminocaproic acid, aprotinin, and tranexamic acid were tested, albeit unsuccessfully.306-
308 Recently, a phase II b trial of recombinant factor VII found a reduced rate of clot 
expansion and improved outcome in the active treatment arm of the trial,309 but the 
phase III trial failed to confirm improvement in outcome at 90 days despite finding the 
same rate of reduced clot expansion (presented by Dr. Stephan Mayer at the 16th 
European Stroke Conference 2007, Glasgow, UK). 
 
2.2.3 Models of intracerebral hemorrhage 
 
The ideal model should show reproducible volumes of hemorrhage, induce hemorrhage 
with mechanism(s) mimicking the clinical situation reasonably well, have the possibility 
of inducing hemorrhage in different regions of the brain by minimal variations of the 
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model, be easy to perform with slight variations among experimenters, and should not be 
burdened with unacceptable cost. Naturally, no model can be 100% relevant to the 
clinical situation, and different models can simulate reasonably well some clinically 
relevant aspects of the condition studied, but their limitations should be considered when 
interpreting study results. Luckily, there are several models to choose from, each more 
or less fulfilling the criteria mentioned. It is indisputable that experimental hemorrhagic 
stroke models are able to reproduce important pathophysiologic events relevant to the 
human situation. Such models helped us substantially in understanding the mechanisms 
and pathophysiology of hemorrhagic stroke and developing novel drugs. This is rather 
important, since, currently, nothing other than basic care is approved for acute medical 
treatment for ICH. The most commonly used ICH models are autologous blood injection 
model and collagenase injection model in the rat. In addition, there exists a balloon 
inflation model and a model of avulsion of cerebral blood vessels. Outcome measures 
include mortality, neurological scoring, behavioral tests, dynamics of the hematoma and 
of the edema growth (using MRI), extent of ischemic injury and apoptosis, 
neuroinflammation, and changes in CBF and ICP. 
 
2.2.3.1 Autologous whole blood-induced ICH 
Blood from an animal, collected from an easily accessible artery, is injected into the 
desired brain region, the basal ganglia (similar to human ICH) being the most common 
site of injection. Blood can be injected into virtually any brain region; but injection into 
the cortex is often complicated by SAH.310 As for the volume of injected blood, range of 
variation among projects is wide, but 50 µl is the volume used most commonly. This 
amount of blood, when injected over a sufficiently long period within the stereotactically 
determined target area, produces hematomas that do not usually leak into compartments 
different from those desired: not, for instance, into intraventricular, subarachnoidal, or 
subdural space. 
 
Although some researchers do inject larger volumes (up to 100 µl), such an approach 
may elevate ICP and lead to complications due to systemic effects.311 Experience from 
our own laboratory suggests that 50 µl of blood injected with a Hamilton syringe slowly 
over 5 minutes results in reasonably good reproducibility of hematoma volumes. It 
should be mentioned that faster injections of larger volumes lead to backflow of the 
injected blood along the needle track, the direct tissue damage in a larger area than 
desired, to interstitial blood drift along the corpus callosum, or even to rupture into the 
brain ventricles (intraventricular hemorrhage). For these reasons, we keep the injection 
time constant (2 µl per 12 sec) and, before injecting the blood, we slightly withdraw the 
Hamilton syringe by 0.5 mm, thus producing a small pouch. Such an approach usually 
prevents backflow of blood and resultant intraventricular hemorrhage. Other 
researchers11,312 have used double injection, i.e., the desired volume of blood injected at 
slow rate in two phases with a 7-minute break in between. In the first phase, a relatively 
smaller volume of blood is injected. It is possible that such a break will, however, lead to 
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clotting of blood along the needle track. For the same purpose, we keep the needle 
inserted at the site of injection for another 3 to 5 minutes after blood injection.  
Our model is associated with approximately 30% 24-hour mortality, depending on the 
animal strain used. 
 
2.2.3.2 Collagenase-induced ICH 
In this model, described by Rosenberg and coworkers,313 ICH is achieved by injection of 
bacterial collagenase into the basal ganglia region. As in the previous model, collagenase 
can be injected into virtually any brain region. The injection leads to degradation of one 
of the most important determinants of the basal lamina: collagen type IV. This produces 
the BBB leak, which in turn leads to extravasation of erythrocytes, eventually producing 
a solid hematoma. One can change the injected amount of bacterial collagenase. 
Rosenberg and coworkers313 injected a range of 0.1 to 1 units of bacterial collagenase 
diluted in 2 µl of saline, with 0.5 units achieving the desired conditions. The final size of 
the hematoma correlates well with the amount of injected bacterial collagenase.314 A 
major modification by Del Bigio and coworkers,289 was injecting 0.14 units diluted in 0.7 
µl saline. Interestingly, these authors added 1.4 units of heparin, leading to rather rapid 
evolution of the hematoma. Such hematomas not only show reasonable reproducibility, 
but appear in with uniform shapes as well. To exclude the possibility of collagenase’s 
affecting other than the brain region desired, an elegant approach was chosen by Mun-
Bryce and coworkers,315 in which the very tip of the collagenase injector was filled with 5 
µl of saline. 
 
2.2.3.3. Balloon inflation model 
This is a less commonly used mechanical model of ICH described by Sinar and 
coworkers,316 studying the mass effect of a hematoma and of its removal on ischemic 
brain injury. Since the inflation is confirmed by x-ray, the inflating material must be a 
contrast agent. Modifiable variables of this model are balloon volume and inflation 
duration, which makes this mechanical model quite reproducible. 
 
2.2.3.4 Cortical blood vessel avulsion 
This is a rather infrequently used simple model of cortical injury, in which the surface 
cortical blood vessels are stripped, whereafter, avulsion of the veins leads to cortical 
ICH.317,318 This model causes not only hemorrhage, however, but ischemic infarction as 
well; a fact which makes reliable comparison with other models rather challenging. 
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2.2.3.5 Summary of intracerebral hemorrhage models 
The autologous blood injection model mimics ICH reasonably well, but the duration of 
injection and time to reach desired hematoma volume is significantly shorter than for 
events leading to spontaneous ICH in human beings. Furthermore, this model lacks a 
bleeding blood vessel. In the collagenase model, the bleeding occurs as soon as 10 to 30 
minutes after injection, but develops rather slowly into a full hematoma 4 to 24 hours 
later.289,313 Brain edema reaches its maximum 24 hours after induction in the blood 
injection model, remaining stable for several days,277 and causes measurable 
deterioration in neurological function. 
 
In the collagenase model, cerebral edema has already developed within 4 hours after 
injection and is resolved 48 hours later, being temporarily associated with neurological 
outcome.313 Certainly, collagenase injection is simpler to perform and is not complicated 
by backflow of the blood along the needle track. Moreover, the amount of collagenase 
injected corresponds well to the hematoma’s final size. 
 
However, the cause of hemorrhage in this model differs from the clinical situation, and 
collagenase itself causes a robust inflammatory reaction which may cause early 
degradation of the hematoma,289 with neutrophils contributing to delayed ICH-induced 
deterioration. Furthermore, inflammation and cell death occur earlier and are more 
prolonged in the collagenase model than in other methods.318 Although anatomically the 
brain injury is most appropriate in the collagenase model, it is rather artificial 
biologically.318 The additional inflammatory changes differ the collagenase model from 
the clinical situation and from the blood injection model, which resembles the clinical 
scenario perhaps more faithfully.318 
 
In the autologous blood injection model, neutrophil infiltration begins within 24 hours, 
peaks at 2 to 3 days, and disappears at between 3 to 7 days.9,290 CD8a-positive, possibly 
natural killer T-lymphocytes became apparent at 48 hours and persisted until 1 week.9 
Microglial reaction was evident at 4 hours, was maximal at 48 to 72 hours, and persisted 
for 4 weeks.9,11 The temporal pattern of neutrophil infiltration is similar, although much 
more robust, in the collagenase model.289,318 
 
In the blood injection model, cell death is maximal at 42 to 72 hours, with apoptosis 
already present at 6 hours, peaking at 3 days and continuing for at least 2 weeks after 
induction.9,319 On the other hand, the collagenase model shows apoptosis within the first 
24 hours after injection, peaking at 3 days and lasting at least 4 weeks.10 The mechanical 
balloon inflation model was found to cause cell death involving apoptosis 6 to 24 hours 
after deflation. 320 
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2.3 Mast cells 
2.3.1 Basic characteristics 
 
MCs are well known to be effector cells of inflammation and immunity.321,322 They were 
first recognized by Friedrich von Recklinghausen in 1863, and their current name comes 
from the German word “Mastzellen” (well-fed cells, feeding cells) used by Paul Ehrlich 
in 1878.323 Ehrlich observed that their cytoplasm is filled with prominent granules, and 
he identified MCs by their metachromatic properties,324 which depend on the presence 
and degree of sulfation of proteoglycans such as heparin and heparan. MC identification 
by their metachromasia permits detection of MCs also in the brain.325,326 MCs are derived 
from the pluripotential stem cells of the bone marrow that produce all hematopoietic 
cells.327,328 
 
The number and distribution of MCs vary among individuals, species, and between 
genders; the sources of this variability are not well known. MCs contain granules that 
store preformed effector molecules, mediators, which are released upon activation in a 
process called compound exocytosis or degranulation.329 MCs can be activated by 
different factors, they are capable of releasing various mediators, and—due to their ideal 
position—they can respond to a wide selection of stimuli.330 
 
Besides releasing the stored content, activation of MCs triggers de novo synthesis and 
secretion of other mediators, including LT, PG, cytokines, and chemotactic factors, which 
produce profound inflammatory and vasoactive effects on the local tissue milieu. 
 
2.3.2 Differentiation, heterogeneity, location, and abundance 
2.3.2.1 Differentiation 
MCs leave the bone marrow as immature cells, committed precursors,331 before they 
home into specific tissues and then undergo differentiation under the specific 
microenvironmental conditions of the homing tissue.327,332 
 
Some authors report that MCs enter the brain as relatively mature cells, with numerous 
secretory granules, along penetrating blood vessels.333 Others326 note that immature MCs 
(containing only a minuscule amount of small granules) infiltrate the CNS and undergo in 
situ differentiation within the neuropil, a finding generally accepted.327,332 
 
It is well established that MC differentiation is dependent upon expression of the stem-
cell factor (SCF, c-kit ligand) in tissues and c-kit on precursor-cell surfaces.334 However, 
Shanas and coworkers335 showed experimentally that brain MCs lack expression of the c-
kit receptor necessary for MC survival and suggested that the special microenvironment 
of the CNS may provide factors other than SCF that sustain MC survival. Two factors, IL-
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3336 and nerve growth factor (NGF),335,337 were suggested. Still, Shanas and coworkers335 
admitted the possibility that the c-kit receptor is present, but not recognized by the 
antisera used, or that c-kit expression or translation of the mRNA or both may be down-
regulated. 
 
2.3.2.2 Heterogeneity 
Since MC differentiation occurs within organotypic tissue compartments, and MCs acquire 
phenotypes specific to their local microenvironment, MCs have a noteworthy 
heterogeneity.327 This phenotypic diversity of MC populations, supported by both human 
and experimental data, means they possibly express different functions in health and 
disease.327,328 At least three types of mature MCs are identified in rodents: serosal (lung, 
peritoneum, skin), mucosal (nasal, gastrointestinal), and brain (dural, perivascular, 
parenchymal),338 although some debate whether brain MCs constitute a distinct 
type.330,338 
 
MCs may, however, have a wider range of phenotypic heterogeneity, as assessed by 
their morphology, histochemistry, response to different drugs and stimuli of activation, 
and the qualitative and quantitative content of mediators they can release.339 
Fundamentally, serosal (connective tissue) MCs contain rat MC protease-I, heparin, 
tryptase, and chymase, whereas mucosal MCs store rat MC protease-II, chondroitin 
sulfate, and tryptase.334 
 
Since brain MCs contain not only histamine but also heparin and rat MC protease-I, they 
resemble connective tissue (serosal) MCs.340 Others341,342 have proposed parenchymal 
brain MCs to be of the classical connective tissue type, as, in the rat, is the case for MCs 
within the connective tissue coverings, i.e., meninges of the nervous system.343,344 
Interestingly, some authors340 showed that brain MCs lack the FcεRI receptor, which 
binds IgE, suggesting that brain MCs do represent a distinct phenotype.335 However, 
brain MCs showing functional FcεRI-bound IgE receptors were purified by others.345 
 
Once acquired, the MC phenotype is not permanent, since mucosal MCs can develop 
into connective-tissue MCs under proper microenvironmental conditions of the local 
milieu, mostly depending on the unique framework of local growth factors, stage of 
development, and the presence or absence of immune activation.334,339 Furthermore, 
adjacent astrocytes may influence the phenotype or the migration of MCs,346 since 
astrocytes synthesize MC growth factors such as IL-3347,348 and NGF349. Accordingly, 
changes in the expression of MC-stimulating factors such as SCF, NGF, and IL-3, -4, -9, 
and -10, all alter the content of stored mediators produced by MCs.321 Finally, the palette 
of mediators may vary between species, e.g., serotonin, a significant mediator in 
rodents, is absent from the MCs of higher mammals.339 
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2.3.2.3 Location 
MCs, resident cells in the brain,327,330 are often observed in close proximity to neurons in 
different peripheral tissues.339 That MCs are present within the nervous system has been 
known for over 100 years,350 and since then, the presence of MCs in the vertebrate brain 
has been accepted.330,338,339,351 MCs enter the CNS during development via penetrating 
blood vessels with which they remain associated,333 as shown by electron microscopic 
studies demonstrating the predominantly perivascular location of MCs.341,352  
 
The known association of MCs with the vascular bed (preferentially at branching points) 
during development is dependent on contact of the blood vessel with astroglial 
processes; such adhesion to the vascular wall during development is suggested to 
involve MC-expressed α4-integrins.353 In addition to their proximity to ECs, MCs reside 
close to fibroblasts, epithelial cells, or nerves,327 all of which are important targets for 
mediator/cytokine action. 
 
In mammals, MCs are typically found in the dura mater, leptomeninges, choroid 
plexus, and the thalamus.325,330,338,351 In the latter, they reside on the neuropil surface 
of the BBB.341,351 They also occur in the olfactory bulb, hypothalamus, and 
mesencephalon,342,343 and in the cerebral cortex,15,330,338 often—again—at the branching 
points of cortical penetrating arterioles. 
 
2.3.2.4 Mast cell abundance in the brain 
Although for unknown reasons, alterations appear in abundance of MCs in the brain, 
which may be caused by changes in marker-dependent detection, by the rate of both 
precursor entry and their differentiation activity, and by MC proliferation.326 It is 
generally accepted that MCs circulate as devoted precursors rather than as mature cells. 
 
But what is also possible (due to the rate of increase of a mature MC population in the 
adult brain) is that mature MCs translocate from peripheral sources into the CNS.354 In 
that study, migrated donor MCs represent 2 to 20% of the total MC population in the 
analyzed brain region one hour after injection, suggesting fast crossing of the BBB. In the 
same study, reconstructions of confocal images showed that MCs were localized deep in 
the basal lamina, in nests of glial processes. Furthermore, electron microscopic analysis 
showed that MCs indeed migrate into the CNS.355 
 
Although fully differentiated MCs as well as their precursors have been considered to be 
able to divide,356 no evidence of MC division was found through BrdU labeling,357 
supporting the hypothesis that increase in end-organ MC population is apparently due to 
migration from the periphery or entry of new precursors from the circulation. Since 
mature cells do not circulate in the blood, it is suggested that the source of the 
augmented population is likely to be via the pial sheath of the thalamic blood 
vessels.333,351 
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The mechanism of MC transmigration into the brain capillary endothelium and its basal 
lamina is unknown, but angiogenic factors do stimulate MC migration in the periphery.358 
Furthermore, MCs, like other immune cells, can adhere to the endothelium and exhibit P-
selectin-dependent rolling activity.359 MCs also contain many proteases (such as 
chymase, tryptase, gelatinases, and cathepsin G), which can enzymatically create a 
temporary pathway through the endothelial junctions and the ECM of the basal lamina. 
This is supported by the fact that peripheral MCs are able to migrate from a connective 
tissue across the basement membrane to access the epithelium.360 Moreover, in vitro 
data show that both dormant and activated MCs can attach to and/or move across a 
variety of structures,361,362 one of them laminin, for which MCs have receptors.361,362 
Laminin occurs in the basal lamina of brain ECs and can be produced by astrocytes as 
well.363 
 
Glial cells may also promote further MC movement by secreting matrix molecules364 or by 
the expression of chemotactic factors such as transforming growth factor-β1365 or IL-
3347,348; the former, an MC mediator itself,330 belongs among potent chemoattractants, as 
well,366 and is also produced by astrocytes.365 Suggesting the existence of some kind of 
autoregulatory mechanism, resident MCs can recruit other MCs by secreting ATP367 and 
NGF.368 
 
2.3.3 Activation  
 
MCs show both IgE-dependent explosive (anaphylactic) degranulation and a more 
controlled (piecemeal) secretory process in response to non-IgE-related stimuli.369 
Degranulation is a stereotyped cascade of stimulus-activated events, biochemical and 
morphologic, which results in the fusion of the cytoplasmic granule membranes with the 
plasma membrane (with extracellular release of granule-associated mediators). Since 
degranulation of MCs per se is not associated with changes in the normal ultrastructure 
of the surrounding neuropil and no other immune-system cells are present, this suggests 
that the secretion occurs ad hoc without ongoing inflammation or imminent tissue 
damage.330,370 Alternatively, MCs can secrete mediators without overt 
degranulation,352,371 through differential or selective release.372 
 
2.3.3.1 FcεRI-mediated activation 
FcεRI is expressed on the MC surface,373 and when adjacent FcεRIs are bridged (by 
antigens interacting with receptor-bound IgE, or by antibodies directed against either 
receptor-bound IgE or the receptor itself), the cells are rapidly activated and release their 
mediators. Bridging of only a few hundred pairs of IgE molecules is sufficient to trigger 
histamine release.374 Because so few MC FcεRI’s must be bridged to initiate the 
degranulation response, MCs cells may be simultaneously sensitized with IgE antibodies 
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of various specificities; they can therefore react to stimulation by many different 
antigens, which constitutes the basis for the stereotypic ‘bulk’ response of MCs in IgE-
dependent immune reactions and allergic disorders.322 
 
2.3.3.2 Nonimmunologic direct activation 
A wide range of biologic substances, including products of complement activation, 
acetylcholine, and PAF, but also mechanical trauma, ionization, changes in pH, and iodine 
contrast agents can provoke MC degranulation and the release of MC mediators.322,339,375 
The sensitivity of different populations of MCs to individual stimuli varies, however.339,375 
Moreover, these stimuli can induce a pattern of mediator release that differs from the 
one associated with FcεRI -dependent MC activation. 
 
2.3.4 Mediators 
 
MC granules are loaded with an armamentarium of bioactive molecules: mediators. These 
mediators are performed or newly synthesized or both, which is the case for certain 
cytokines. It should be mentioned that although MCs produce a variety of mediators, no 
single MC subtype synthesizes the whole possible repertoire.330 
 
2.3.4.1 Preformed mediators 
Preformed mediators stored in the cytoplasmic granules include biogenic amines, 
proteoglycans, serine proteases, carboxypeptidase A, and small amounts of sulfatases 
and exoglycosidases. 
 
Histamine is well known for its effects in allergic skin reactions like itching and swelling. 
It is a potent vasodilator and also mediates an immediate increase in vascular 
permeability; hence it contributes to capillary leak and edema formation in peripheral 
tissues and epithelium.376 MC-derived histamine regulates expression of selectins in ECs 
with consecutive rolling of leukocytes.376 Studies in genetically MC-deficient and normal 
mice indicate that MCs account for nearly all the histamine content stored in normal 
tissues, with the exception of the glandular stomach and the central nervous system. In 
the latter, MCs contribute up to 90% of the histamine content in the thalamus and up to 
50% of whole brain histamine levels.377 Other biogenic amines stored in MCs are the 
neurotransmitters dopamine and serotonin. 
 
Proteoglycans are major constituents of MCs,326 and MCs are the only endogenous 
cellular source of heparin in mammals.378,379 Depending on location and age, human MCs 
can produce proteoglycans of the chondroitin sulfate and heparin sulfate type within the 
same cell, or individual cells may make only one.380 Proteoglycans have several biologic 
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functions both within and outside the cells. They bind histamine, neutral proteases, and 
carboxypeptidases, and they may contribute (especially serglycin) to the packaging and 
storage of these molecules within the granules.381 
 
Heparin can inactivate the serine protease thrombin. Specific sulfated pentasaccharide 
units in heparin glycosaminoglycans can bind antithrombin III, a protein that circulates in 
the blood, inducing an allosteric change and to a great extent enhancing its anti-clotting 
activity.378,379 Studies in genetically MC-deficient mice382 show that the natural 
anticoagulant properties of the vasculature reflect the presence of the heparan sulfate 
proteoglycans—not the heparin proteoglycans—on the surface of the ECs that line blood 
vessels.379,382 As suggested by Forsberg and coworkers,383 endogenous heparin cannot 
play a physiological role in regulating blood coagulation, since it is absent from the blood. 
Heparin and heparans are also well established as molecules necessary for the activity of 
some growth factors such as the fibroblast growth factor family. 
 
Neutral proteases represent another major protein component of MC granules, where 
tryptase is the major enzyme stored in the cytoplasmic granules of all human MCs322; 
hence its measurement in biologic fluids such as plasma, serum, and inflammatory 
exudates can aid in assessing MC activation. 
 
Tryptase is a serine endopeptidase stored in the granules in active form, which is 
stabilized by its association with heparin and perhaps other proteoglycans.322 In the rat, 
only connective tissue MCs contain tryptase.384 Chymase, another serine protease stored 
in active form in the granules of some human MCs, seems to play a major role, together 
with tryptase, in the proteolytic activation of latent forms of MMP-1, MMP-2, and MMP-
9,18,385-387 as well as in the physiologic degradation of tissue fibronectin and thrombin.388 
Pro-MMP-9 is a substrate for chymase in vitro.389 
 
MCs themselves can release MMPs, in specific the gelatinases A (MMP-2) and B (MMP-
9),109 although it is debated whether latent MMP-9 coexists with histamine and tryptase 
in the granules111 or is produced de novo.88 The latter is supported by the finding of the 
MMP-9 protein being first detected at 6 hours and peaking at 22 hours after MC 
activation.88 Cathepsin G, also produced by neutrophils and monocytes/macrophages, is 
a MC-derived protease which cleaves many components of the extracellular and 
pericellular matrix including fibronectin and vitronectin.390 Last but not least, another 
serine protease, TPA, belongs to the palette of MC mediators.376 
 
2.3.4.2 Newly synthesized mediators 
Some of the MC mediators are not stored but are produced de novo and secreted only 
upon appropriate stimulation of the cells.375 Of particular importance are the 
cyclooxygenase and lipoxygenase metabolites of arachidonic acid, which have potent 
inflammatory activities and which may also play a role in modulating the release process 
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per se.375 The major cyclooxygenase product of MCs is neuromodulator PGD2,
391 and the 
major lipoxygenase products derived from MCs are the sulfidopeptide LTs: LTC4 and its 
peptidolytic derivatives, LTD4 and LTE4. Human MCs can also produce LTB4, albeit in 
much smaller quantities than PGD2 or LTC4.
375 PAF, another MC mediator, has substantial 
chemoattractant, vasoactive, and platelet-activating properties implicated in brain 
injury.392 
 
2.3.4.3 Cytokines 
Cytokines are a diverse group of glycoproteins synthesized and, typically, secreted by 
many cell types in response to their activation or injury. Cytokines can modulate both 
specific immune responses and immunologically nonspecific inflammation by alteration of 
the function or gene expression in responding cells. MCs are a source of a number of 
cytokines.16,322 Much of the ability of certain cytokines (IL-1, TNF-α) to promote allergic 
inflammation is thought to reflect the ability of these agents to enhance the recruitment 
of leukocytes by inducing increased expression of adhesion molecules such as P-selectin 
and E-selectin, vascular cell adhesion molecule-1, and ICAM-1, on ECs.393,394 
 
TNF-α represents a distinct type of MC mediator, since it is derived from both preformed 
and newly synthesized pools.334 Being probably the only cell type containing preformed 
stores of TNF-α,395 MCs are likely to represent a critical initial cellular source of TNF-α 
during inflammation.322 Later during the inflammation response, TNF-α is produced by 
neutrophils, eosinophils, T and B cells, and macrophages.16 TNF-α promotes leukocyte 
infiltration through its effects on ECs and leukocytes, as well as promotes inflammation, 
granuloma formation, angiogenesis, and tissue fibrosis; MCs are involved in all these 
processes.334 It should be noted, however, that most studies investigate release of 
cytokines upon activation via the FcεRI, and little is known as to whether indirect 
activation of MC leads to similar effects. 
 
2.3.5 Mast cell functions and related disorders 
 
Originally, Ehrlich thought that MCs help to maintain the nutrition of connective 
tissues.323 Nowadays, it is widely accepted that MCs serve the host by many different 
functions in health and disease. Some evidence indicates that MCs participate in bacterial 
recognition, followed by endocytosis, processing and presentation of bacterial antigen, 
immune cell recruitment, and elimination of parasites.321,396,397 In addition, MCs are 
involved in blood clotting, wound repair, and tissue remodeling.16,398,399 
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2.3.5.1 Type-1 hypersensitivity 
Type-1 hypersensitivity is an allergic reaction provoked by re-exposure to a specific type 
of antigen, an allergen. In peripheral tissues, MCs play well-established roles in 
mediating inflammation and allergic responses during the host response to various 
environmental challenges.334 The allergic reaction is generally divided into the acute 
(immediate) response mediated largely by degranulation and the late-phase response 
(LPR) resulting from MC activation and synthesis of de novo mediators. 
 
The acute response is the pathophysiologic hallmark of allergic rhinitis, allergic asthma, 
and anaphylaxis. An immediate hypersensitivity reaction is initiated on the surface of 
MCs by the interaction of antigen-specific IgE molecules with the relevant antigen. The 
physiologic effects are due to the biologic responses of target cells (e.g., ECs, smooth 
muscle cells, glandular cells, and leukocytes) to mediators released by activated MCs. 
Besides allergens, other stimuli like certain activated complement fragments 
(anaphylatoxins C3a and C5a), neutrophil lysosomal proteins, peptides and peptide 
hormones, venoms, radiocontrast agents, cold exposure, calcium ionophores, narcotics, 
and muscle relaxants, may lead to the acute response and rapid release of mediators 
from MCs independently of IgE.375 
 
The LPR follows the acute response by 4 to 8 hours as persistent swelling and leukocyte 
infiltration. Many of the consequences of IgE-dependent reactions are caused by the 
actions of the leukocytes recruited during the LPR rather than the direct effects of the 
initial release of MC mediators.394 
 
It has been suggested that “MC-leukocyte-cytokine cascade”334,394 makes a critical 
contribution to the initiation and perpetuation of IgE-dependent allergic inflammation in 
the airways and at other sites. Specifically, what is proposed is that activation of MCs 
through the FcεRI initiates the response, in part through the release of TNF-α and other 
cytokines that can influence the recruitment and function of additional effector cells. 
These recruited cells can consequently promote further progression of the inflammatory 
response by providing additional sources of certain cytokines. 
 
2.3.5.2 Demyelinating diseases 
The role of MCs in brain pathology was thus far rather ignored, even though their 
presence in the nervous system was demonstrated more than a century ago, in 1890, 
when they appeared in brain infarcts and at the edge of multiple sclerosis plaques.350 
One hundred years later, MCs have been suggested to serve as a link between the 
immune, endocrine, and nervous systems, to play an important role in the access of 
lymphocytes and pathogens to the brain,338 and to be involved in mediating changes in 
blood flow, neurotransmission, and local immune responses in the brain.330 
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Further research concerning MCs’ role in autoimmune demyelinating diseases 
demonstrated the ability of their neutral proteases to degrade myelin.400,401 MCs 
degranulate upon exposure to myelin basic protein and can induce peripheral402 and 
central403 demyelination. Furthermore, the MC-specific enzyme tryptase is significantly 
elevated in the CSF of multiple sclerosis patients.404 It is of interest that the Theoharides 
group405 performed a pilot open-label clinical trial using hydroxyzine (histamine-1 
receptor antagonist) in multiple sclerosis, concluding that hydroxyzine could serve as an 
adjuvant therapy in multiple sclerosis. However, the small number of enrolled patients 
and the short duration of the study precluded any definitive conclusions. 
 
2.3.5.3 Excitoxicity and cerebral ischemia 
Recently, Patkai and coworkers406 demonstrated that brain MCs may contribute to the 
exacerbation of neonatal excitotoxic brain lesions produced by IL-9, suggesting a role for 
MCs in neonates at risk for cerebral palsy. Regarding excitotoxicity, reports showed that 
CNS neurons can acquire MC products at least in three ways370 and that MC modulation 
causes excitation or inhibition of thalamic neuronal activity.407 Skaper and coworkers408 
demonstrated that histamine potentiated NMDA receptor-mediated excitotoxicity in 
cultured hippocampal neurons and suggested a role for MCs in conditions under which 
enhanced glutamatergic neurotransmission occurs in conjunction with tissue acidification, 
such as epilepsy and cerebral ischemia. 
 
Supporting this hypothesis, degranulation of MCs appeared to be dependent on local pH, 
which influenced the dissociation rates of proteoglycan-associated mediators; for 
instance, histamine is released very rapidly, with tryptase and chymase released much 
more slowly.322 Such a pH-dependent occurrence may be relevant to the local lactate 
acidosis that prevails under ischemic conditions. 
 
Indeed, brain MCs are demonstrated to be involved in cerebral ischemic insults,409-411 
with a role for MCs in cerebral ischemia and hemorrhage (I-III). Later, Jin and 
coworkers412 found a rapid increase in cerebral populations of MCs and in their activation 
in association with hypoxic-ischemic (HI) brain damage in the immature rat. Activated 
MCs were present in the pia mater and parenchyma as well, and, importantly, were 
found in those regions showing neuronal loss. Those in the latter region were significantly 
reduced by MC stabilization, administered either pre- or post-HI or post-HI only. Jin and 
coworkers412 observed a very important phenomenon: that hypoxia alone did not lead to 
MC-dependent brain damage, even if it was associated with elevated MC count and with 
some level of MC degranulation. This suggests that MCs react rather differently to 
different stimuli and not necessarily always by full-blown degranulation. 
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2.3.5.4 Other conditions 
MCs have been reported to be actively involved in a range of other conditions, including 
migraine, inflammatory arthritis, atopic dermatitis, coronary inflammation, interstitial 
cystitis, irritable bowel syndrome,413 atherothrombosis,414 angiogenesis, tissue damage, 
neoplasms, blood clotting, wound repair and tissue remodeling,16,398,399 and are found in 
human cerebral arteries after aneurysm rupture.415 
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3 AIMS OF THE STUDY 
 
The aims of the study included in this thesis were to test the hypothesis whether mast 
cells play a role in the pathophysiology of ischemic stroke and intracerebral hemorrhage 
by use of in vitro and in vivo experiments. The latter examined pharmacological 
modulation of mast cell degranulation by application both of stimulatory and of inhibitory 
interventions. In addition, genetically modified mast-cell-deficient rat strains allowed 
authentication of the hypothesis behind the studies. 
 
Specific questions elucidating possible mast cell involvement included: 
 
1. Do mast cells play a role in the regulation of blood-brain barrier permeability 
following transient focal brain ischemia? 
 
2. Are mast cells involved in promoting further sinister consequences of spontaneous or 
tissue plasminogen activator-mediated ischemia-reperfusion injury, such as 
development of brain edema and hemorrhage and neutrophil infiltration? 
 
3. Is there a role for mast cells in regulating the growth of hematoma and expansive 
brain edema in intracerebral hemorrhage? 
 
4. How are these effects of mast cell modulation related to neurological outcome and 
mortality? 
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4 MATERIALS AND METHODS 
 
All experiments were carried out in Biomedicum Helsinki. The animal research committee 
approved all studies. All experiments were blinded, and group assignments were 
randomized. 
 
4.1 Anesthesia 
Experimental animals were adult male Wistar rats (Harlan Nederland, Horst, The 
Netherlands), and MC-deficient WsRcWs/Ws rats (Japan SLC, Inc., Tokyo, Japan), 290 to 
340 grams. Anesthesia was achieved by an intraperitoneal injection of ketamin 
hydrochloride (50 mg/kg, Ketalar, Parke-Davis, Detroit, MI, USA) and a subcutaneous 
injection of medetomidine hydrochloride (0.5 mg/kg, Domitor, Orion, Espoo, Finland). 
 
4.2 Measurement/monitoring of physiological parameters 
A polyethylene tube was inserted into the left femoral artery for blood pressure 
monitoring (Olli Blood Pressure Meter 533, Kone, Espoo, Finland) and for collecting blood 
samples for measurement of arterial pH, blood gases, and blood glucose (AVL OPTI, 
Roche, Basel, Switzerland), and another tube into the left femoral vein for drug or vehicle 
infusion or both. Rectal temperature was maintained at 37 °C during the surgery with 
a heating blanket and a heating lamp. 
 
4.3 Focal cerebral ischemia model 
Transient focal cerebral ischemia was induced by the suture occlusion model. The right 
CCA and the right ECA were exposed through a ventral midline neck incision. The 
proximal CCA and the origin of the ECA were ligated. A 4-0 nylon monofilament suture 
(Ethilon Nylon Suture, ETHICON Inc., Somerville, NJ, USA) with its tip rounded by 
heating near a flame and then coated with silicone (Bayer, Leverkusen, Germany) was 
inserted into the right CCA via an arteriectomy approximately 3 mm below the right 
carotid bifurcation and was advanced into the ICA approximately 17 mm above the 
carotid bifurcation. At that point, a slight resistance is felt, indicating that the occluder is 
lodged in the ACA, thus occluding the orifice of the MCA, the ACA, and the posterior 
communicating artery. This model mimics well large hemispheric strokes, which are 
complicated with malignant swelling. 
 
Blood pressure and body temperature were continuously monitored and recorded every 
30 minutes. Reperfusion was accomplished by withdrawing the suture occluder 60 (I) 
or 90 (II) minutes after MCA occlusion. Sham-operated animals underwent the same  
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procedure, except that the suture occluder was inserted only 10 millimeters above the 
carotid bifurcation and was withdrawn one minute later. At the end of the experiment, 
the femoral catheters were removed, operation wounds sutured, and the animals allowed 
free recovery in separate cages. 
 
4.4 Cardiac perfusion and tissue handling 
After various periods of time following reperfusion, the rats were re-anesthetized with an 
intraperitoneal injection of 120 mg of pentobarbital sodium (Mebunat, Orion, Turku, 
Finland), and cardiac perfusion was performed. Briefly, the chest was opened, a catheter 
was inserted into aorta via the left ventricle while the heart was still beating but 
respiration had ceased, and 200 mL of ice cold 0.9% saline was infused at 100 mmHg 
inflow pressure into the arterial vascular system. Simultaneously, the right atrium was 
incised open to allow all the blood to be drained. 
 
After cardiac perfusion, the brains were quickly removed and dissected coronally into six 
2-mm-thick slices with a standard brain-cutting matrix. Each third slice was cut into two 
1-mm portions (rostral and caudal). The rostral part was embedded in Tissue-Tek 
(Sakura Finetek Inc., Tokyo, Japan), snap-frozen in liquid nitrogen, and kept thereafter 
at -80 °C until 15-µm sections were cut for BBB permeability analysis. 
 
Then 5-µm sections were cut from the caudal site of all slices and stained with a) 
hematoxylin-eosin; b) Toluidine blue, a standard metachromatic histopathological 
technique to detect the heparin-containing granules present exclusively in MCs (I, Figure 
1A,B); and c) chloracetate esterase (Leder)416 staining to detect polymorphonuclear 
neutrophils. Toluidine blue is an aniline dye to which MCs display the property of 
metachromasia, due to the dye’s binding to sulfated glycosaminoglycans in MC 
granules.417 The remaining slices were incubated for 15 minutes in 2,3,5 
triphenyltetrazolium chloride (TTC) at 37 °C, and subsequently immersion-fixed in 
10% formaldehyde. 
 
4.5 Laser-Doppler flowmetry 
CBF was measured by the BF/F/0.5 bare-fiber flexible probe of the Oxy-Flow device 
(Oxford Optronix, Oxford, UK). The scalp was incised in the midline and the skull 
exposed. The skull was thinned by a dental drill at an area ipsilateral to the ischemia 
between 1.0 to 2.5 mm posterior and 6.0 to 1.5 mm lateral from the bregma. The probe 
was attached, within the thinned area, to the skull surface at a place of representative 
baseline CBF signal. The CBF signal was then obtained from the same place throughout 
the entire experiment. 
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4.6 Intracerebral hemorrhage model 
For ICH, we used the autologous whole blood injection model described 
elsewhere.272 The head of the animal was fixed into a stereotaxic frame (Stoelting, 
Wood Dale, IL, USA) and a midline scalp incision was made to disclose the calvarium of 
the skull. A burr hole (1 mm in diameter) was drilled on the right side of the cranium: 
0.2 mm anterior and 3.0 mm lateral to the bregma. A 27-gauge needle attached to a 
Hamilton syringe was inserted into the core of the right basal ganglia (at a 6.0 mm 
depth from the skull surface) and subsequently lifted by 0.5 mm, creating a small cavity. 
Then, 50 µl of freshly collected homologous arterial blood was injected into the brain 
slowly over 5 minutes, after which the needle was kept in place for 3 minutes. The burr 
hole was sealed with bone wax, and the scalp was sutured. 
 
Twenty-four hours later, the animals were terminated with an overdose (120 mg) of 
sodium barbiturate (Pentobarbital, 1 mL, intraperitoneally) and underwent cardiac 
perfusion with 200 ml of ice-cold saline (see above). Afterwards, the brains were 
harvested, cut through the site of the intracerebral blood injection into 2 blocks (in order 
to examine the hematoma at its largest epicenter), and photographed with a digital 
camera (Sony Mavica, Tokyo, Japan). 
 
4.7 In vitro assay of TPA-mediated MC degranulation 
Rat peritoneal MCs were obtained from Wistar rats by an experienced coworker as 
described.418 A standard amount of 2x105 MCs in 50 µl of phosphate-buffered saline were 
placed into Eppendorf tubes and preincubated for 10 min at 37 °C. Then, freshly 
prepared TPA solution (Actilyse®, Boehringer-Ingelheim, Germany) was added to give 
the final concentrations indicated (ranging from 0 to 50 µg/ml), and incubation was 
continued for 15 min to allow completion of MC degranulation. Immersing the tubes in 
ice-cold water stopped the reaction, and the cells were sedimented by centrifugation at 4 
°C. The histamine concentration in the supernatant was determined fluorometrically 
according to Bergendorff and Uvnäs with modifications.419 Histamine release by TPA was 
expressed as a percentage of the maximal histamine release induced by the standard MC 
secretagogue compound 48/80 (1 µg/ml) set as 100%. 
 
4.8 Drug characteristics and administration 
1. Sodium cromoglycate (Sigma-Aldrich, Steinheim, Germany), a clinically recognized 
inhibitor of MC degranulation, given intracerebroventricularly (icv) to overcome its 
presumed minimal crossing of the BBB.420 Due to a short biological half-life (90 minutes), 
the icv administration of cromoglycate in the 24-hour group (II) was followed by 
continuous icv infusion of cromoglycate with Alzet® osmotic pumps (model 2001, 200 µl, 
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1 µl/hour) and Brain infusion kit 2 (both Durect Corporation, Cupertino, CA, USA) 
according to instructions. 
In Study III, however, in addition to icv administration, an iv route was also used, based 
on a report that cromoglycate was effective in an acute stress model when given iv.421 
This implies that this drug may penetrate into the brain at some extent. 
Cromoglycate was suggested to inhibit MC degranulation by regulating phosphorylation 
of an MC 78-kDa protein involved in the regulation of secretion.422 This protein appears 
to be involved in signal transduction by regulating functional associations between cell 
surface and cytoskeleton.422 
 
2. Compound 48/80 (Benzeneethanamine, 4-Methoxy-N-Methyl-(9CI)*N-(P-
Methoxyphen-ethyl) Methylamine*, Sigma-Aldrich, Steinheim, Germany) is a 
condensation product of N-methyl-p-methoxyphenethylamine with  formaldehyde and is 
a standard MC degranulating secretagogue.341,423,424 It inhibits calmodulin and activates G 
proteins. Compound 48/80 degranulates brain MCs in mammals.341,425 
 
3. TPA (Actilyse®, Boehringer-Ingelheim, Germany) is the only approved 
pharmacological therapy for acute ischemic stroke. Ten mg/kg of body weight is the 
standard dose for TPA thrombolysis in rats in studies focusing both on therapeutic 
efficacy and TPA-mediated hemorrhage.147 
 
4. Drug administration A polyethylene tube was inserted into the left femoral vein for 
drug or vehicle infusions or both. For icv drug administration, the head of the animal was 
fixed in a stereotaxic frame (Stoelting), and a midline scalp incision was made to disclose 
the calvarium of the skull. A burr hole was drilled on the left side of the skull: 0.9 mm 
posterior and 1.6 mm lateral to the bregma. A 27-gauge needle attached to a Hamilton 
syringe was then inserted into the left lateral brain ventricle (at 3.4 mm depth from the 
skull surface), and drug or saline was slowly injected over 3 minutes. 
 
4.9 Study protocols 
In addition to the pharmacological modulation of MCs, genetically modified MC-
deficient WsRcWs/Ws rats426,427 carrying a defective gene for c-kit (ligand for SCF 
required for MC differentiation) were used. In comparison to their WT littermates, 
newborn WsRcWs/Ws rats are MC deficient and anemic. Anemia, however, is already 
ameliorated by the age of 10 weeks, whereas the MC deficiency increases; this has led to 
wide use of adult rats in specific investigations of MC function.426  
 
The present studies used adult rats (13-14 weeks old). Table 2 shows their hematological 
(Coulter Counter T-660, Coulter Electronics, London, UK) and hemostatic markers 
(Coagulometer KC-40, Lemgo, Germany) obtained by a mechanical clot method from rat 
plasma with 3.8% sodium citrate addition, as provided by the supplier (Japan SLC, Inc., 
Tokyo, Japan). 
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Table 2. Hematological markers and coagulation parameters in 12- to 13-week-old MC-
deficient rats (WsWs) and their wild-type littermates 
 
Parameters WsWs (n=10) Wild-type (n=8) 
RBC (x104/mm3) 608.0 ± 10.2 765.0 ± 37.0 
Ht (%) 41.3 ± 1.1 44.2 ± 0.4 
Hb (g/dL) 14.8 ± 0.3 16.2 ± 0.2 
WBC (x102/mm3) 86.0 ± 7.3 93.0 ± 5.3 
BP (x 104/mm3) 99.2 ± 3.5 96.5 ± 2.7 
MCV (fL) 66.5 ± 0.9 52.3 ± 0.4 
MCH (pg) 25.5 ± 0.5 19.4 ± 0.2 
MCHC (g/dL) 38.3 ± 0.3 37.1 ± 0.2 
APTT (sec) 15.0 ± 0.8 16.5 ± 0.3 
PT (sec) 17.6 ± 0.3 18.6 ± 0.4 
RBC/WBC, Red/white blood cell; Ht, Hematocrit; Hb, Hemoglobin; BP, Blood platelets; MCV, 
Mean corpuscular volume; MCH, Mean corpuscular hemoglobin; MCHC, Mean corpuscular 
hemoglobin concentration; APTT, Activated partial thromboplastin time; PT, Prothrombin time 
 
4.9.1 Study I 
Pharmacological modulation: Three groups of rats that underwent transient MCA 
occlusion received cromoglycate or compound 48/80 or saline (Table 3). Furthermore, 
sham-operated animals were included (4 receiving each treatment) (Table 3). Three 
separated groups of animals that underwent transient MCA occlusion were included for 
laser-Doppler measurement: control (n=4), cromoglycate (n=5), and compound 48/80 
(n=4). 
 
Gene manipulation: Afterwards, I induced transient MCA occlusion in MC-deficient rats 
and in their WT littermates (Table 3). 
 
 
Table 3. Study protocols in Study I 
 
            Pharmacological modulation Gene manipulation 
Group Cromo/Sham C48/80 / Sham Control/Sham WsWs Wild-type 
N 14 / 4 11 / 4 13 / 4 10 8 
-5 min cromo icv saline icv saline icv - - 
0 min MCAO / sham MCAO / sham MCAO / sham MCAO MCAO 
57 min saline iv C 48/80 iv saline iv - - 
60 min R / - R / - R / - R R 
cromo icv or saline icv, cromoglycate 750 µg (dissolved in saline to a final volume of 10 µl) or 
saline 10 µl, given intracerebroventricularly (icv); C 48/80 iv or saline iv, compound 48/80 0.5 
mg/ml of saline (200 µl) or saline 200 µl given intravenously (iv); R, reperfusion; follow-up 3 hours 
after reperfusion 
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4.9.2 Study II  
Pharmacological modulation: Several series were performed with different timing of 
experiments. The infusion protocol of TPA was identical to that used in humans (Table 4). 
First, with 6 hours’ follow-up after induction of MCA occlusion, a model to evaluate TPA-
induced hemorrhage formation (HF), inflammatory cell infiltration, and the potential 
effect of the timing of the TPA infusion (before or after reperfusion) was established 
(Experiment 1). 
 
Then, with the same 6-hour follow-up, I focused on the effect of pharmacological MC 
stabilization with cromoglycate on TPA-induced HF (Experiment 2). To assess the effect 
of post-ischemic interval and the treatment effect on the HF and outcome, I performed 
experiments with pharmacological MC stabilization with a 3- and a 24-hour follow-up 
(Experiments 4 and 5). 
 
Gene manipulation: To confirm the role of MCs, I investigated the effect of TPA in 
genetically modified MC-deficient rats and their WT littermates after 6- and 24-hour 
follow-up (Table 4, Experiments 3 and 6). 
 
 
 Table 4. Study protocols in Study II 
 
                      Experiment 1 (6 h) Experiment 2 (6 h) Experiment 3 (6 h) 
Group Sham Saline Early TPA Late TPA Cromo/TPA Saline/TPA WsWs Wild-type 
N 7 7 11 7 10 12 6 4 
-5 min - - - - cromo icv saline icv - - 
0 min sham MCAO MCAO MCAO MCAO MCAO MCAO MCAO 
85 min saline saline TPA saline TPA TPA TPA TPA 
90 min - R R R R R R R 
180 min saline saline saline TPA - - - - 
 
 
                    Experiment 4 (3 h) Experiment 5 (24 h) Experiment 6 (24 h) 
Group Sal/Sal Sal/TPA Cromo/TPA Sal/Sal Sal/TPA Cromo/TPA WsWs Wild-type 
N 6 6 6 7 11 6 6 4 
0 min MCAO MCAO MCAO MCAO MCAO MCAO MCAO MCAO 
15 min saline icv saline icv cromo icv saline icv saline icv cromo icv - - 
85 min saline TPA TPA saline TPA TPA TPA TPA 
90 min R R R R R R R R 
 cromo icv or saline icv, cromoglycate 750 µg (dissolved in saline to a final volume of 10 µl) or saline     
 10 µl, given intracerebroventricularly (icv), and in the 24-hour groups followed by continuous icv  
 infusion of the same concentration of cromoglycate or saline with ALZET® osmotic pumps; saline  
 (Sal) or TPA, intravenous bolus (10%) of calculated dose of TPA (10 mg/kg of body weight dissolved  
 in saline)  or a corresponding amount of saline, followed by 60-minute infusion of the rest of TPA or  
 corresponding amount of saline; R, reperfusion 
    
63 
4.9.3 Study III 
Pharmacological modulation: Four groups of rats received cromoglycate (two groups), 
compound 48/80, or saline 5 minutes before induction of autologous blood injection into 
the basal ganglia (Table 5). 
 
Gene manipulation: MC-deficient rats and their WT littermates underwent the induction 
of ICH without any pharmacological modulation (Table 5). 
 
 
Table 5. Study protocols in Study III 
 
                   Pharmacological modulation                        Gene manipulation 
  Group Control Cromo icv Cromo iv C 48/80 WsWs Wild-type 
N 11 11 10 11 8 8 
-5 min saline icv cromo icv saline icv saline icv - - 
-5 min saline iv saline iv cromo iv C 48/80 iv - - 
0 min ICH ICH ICH ICH ICH ICH 
cromo icv or saline icv, cromoglycate 750 µg (dissolved in saline to a final volume of 10 µl) or 
saline 10 µl, given intracerebroventricularly (icv); cromo iv or C 48/80 iv or saline iv, 
cromoglycate (100 mg/kg of body weight dissolved in saline to a final volume of 200 µl), or 
compound 48/80 (0.5 mg/ml of saline, 200 µl), or saline 200 µl given intravenously (iv); ICH, 
intracerebral hemorrhage 
 
4.10 Magnetic resonance imaging 
MRI scanning was performed with a 4.7 Tesla scanner (PharmaScan, Bruker BioSpin, 
Ettlingen, Germany) using a linear birdcage radiofrequency coil with an inner diameter of 
38 mm. Following shimming and scout images, coronal T2
*-weighted images were 
acquired with a gradient echo sequence (repetition time = 277 ms, echo time = 8 ms, 
flip angle = 35 o, matrix size = 256 × 256, field of view = 40 × 40 mm, number of 
averages = 4, slice thickness = 1 mm). Afterwards, coronal T2-weighted images (T2-WI) 
were acquired by rapid acquisition with a relaxation enhancement sequence (repetition 
time = 5257 ms, effective echo time = 64 ms, echo train length = 16, matrix size = 256 
× 256, field of view = 40 × 40 mm, number of averages = 2, slice thickness = 1 mm). 
The rats were placed in the MRI scanner within 10 minutes after ICH induction. The 
survivors were reanesthetized 24 hours later, and MRI data were collected using the 
same sequences. Baseline data corresponds to 40 to 50 minutes after ICH induction. 
 
Core body temperature during imaging was maintained at 37 o C by use of a MRI-
compatible heating pad and pump (Gaymar Industries, Orchard Park, NY, USA). 
 
MR images correlated very well with histopathological changes in a collagenase model of 
ICH, and the evolving appearance of human ICH on T2-WI images
 has been attributed to 
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the effects of hemoglobin degeneration together with changes in tissue water (edema).289 
T2*-WI is preferentially used to visualize the hematoma in ICH experiments.
245 
 
4.11 Evaluation of the blood-brain barrier damage 
To visualize BBB leakage, animals received a 2% solution of EB albumin (fluorescent dye, 
Sigma, 20 mg/mL dissolved in 1% albumin) into the femoral vein (0.3 mL/100 g) 20 
minutes before cardiac perfusion. EB is a standard method of BBB permeability 
assessment.428 
 
In the experiments with pharmacological modulation of MCs (I), the 15-µm brain sections 
were examined for distribution of characteristic red fluorescence of EB in brain 
parenchyma by epifluorescent microscope Axioplan 2 (Carl Zeiss, Hallbergmoos, 
Germany) and a fluorescence filter specific for EB (Chroma, Rockingham, VT, USA, 
excitation at λ = 620 nm, emission at λ = 680 nm). For evaluation of BBB damage, 
images of 5 pre-specified regions of interest (3 from cortex and 2 from basal ganglia) 
from the infarcted area, as well as a reference image from the healthy hemisphere, were 
captured with an AxioCAM HR digital camera (Carl Zeiss). Digital imaging fluorescence 
microscopy is reliable in measurement of tracer concentration in sectioned tissue.429 
 
We quantified EB-fluorescent pixels with Image J analyzing software (NIH, Bethesda, MD, 
USA). The level of autofluorescence was based on that obtained from the healthy 
hemisphere. For each animal, we calculated the difference between the fluorescence 
signal in five selected regions of interest (represented by the characteristic red 
fluorescence) and the level of autofluorescence. Finally, signals from all five regions of 
interest were averaged. 
 
Following the acquisition of an improved fluorescence scanner Typhoon 9400 
(Amersham Biosciences, Buckinghamshire, UK), a slightly revised technique was adopted 
for the gene-manipulated animals in Study I, and for the entire Study II. With this 
scanner, the difference in average fluorescence signal intensity (Figure 4) between the 
entire infarcted area and the intact hemisphere could be measured by image analyzer 
software ImageQuant (Amersham). 
          
Figure 4. Extravasated Evans blue, digital imaging and fluorescence scanner 
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4.12 Histological evaluation 
Light microscopy was performed by an experienced hematopathologist without prior 
knowledge of animal grouping with an Olympus BH-2 (Olympus, Tokyo, Japan). Findings 
were photographed with a Nikon Eclipse E600 microscope connected to a Nikon Coolpix 
995 digital camera (Nikon, Tokyo, Japan). 
 
The densities of intravascular and emigrated neutrophils were counted in systematically 
placed target areas in 5-µm chloracetate esterase-stained cross-sections through the 
area of maximal infarction. In each area, a total of 60 to 100 microscopic fields of 0.1 
mm2 were counted and averaged. Neutrophil number was counted in the temporoparietal 
infarction core and in the adjacent parasagittal infarct penumbra, as well as in the deep 
thalamic and basal ganglia. 
 
4.13 Calculation of brain infarction and swelling 
All (six) TTC-stained brain slices mounted on a scale were photographed (Figure 5) with 
a digital camera (Sony, Tokyo, Japan). TTC staining has served as a stain to detect 
ischemic infarction since 1958. This water-soluble salt is not a dye and is reduced in 
normal tissue by mitochondrial enzymes (specifically, succinate dehydrogenase) to a fat-
soluble, light-sensitive compound called formazan that turns intact tissue deep red. The 
unstained area represents infarcted tissue. 
 
Figure 5. TTC staining, infarction 
Infarction and corrected infarction volumes were calculated. Briefly, the areas of the 
infarcted tissue and the areas of both hemispheres were calculated for each brain slice. 
The uncorrected infarct volume was calculated by measuring the unstained area in 
each slice, multiplying it by slice thickness, and then summing all six slices. The 
corrected infarct volume was calculated to compensate for the effect of brain edema. 
The difference between the areas of the right and left hemisphere in a slice was 
considered edema and subtracted from the infarct area of that slice (corrected infarct 
area = uncorrected infarct area – [right hemisphere area – left hemisphere area]). The 
result was multiplied by slice thickness, and all six slices were summed to get total 
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corrected infarct volume. Percentage of brain swelling was derived from the 
volumetric growth of the ischemic hemisphere in comparison to the intact one (% of 
hemispheric expansion = [(right hemisphere volume / left hemisphere volume) – 1] * 
100). 
 
4.14 Calculation of hemorrhage formation 
The areas of hemorrhage were calculated from the caudal site of all slices stained with 
hematoxylin-eosin (Figure 7D) by use of an Axioplan 2 microscope (Carl Zeiss, 
Hallbergmoos, Germany). All areas with HF were photographed with an AxioCam MRc 
digital camera (Carl Zeiss) connected to the microscope. Finally, total areas containing 
extravasated erythrocytes and representing intracerebral HF were calculated from digital 
images using Image J analysis software (NIH, Bethesda, MD, USA). 
 
4.15 Calculation of intracerebral hemorrhage, brain swelling, and edema 
Based on the specific signal intensity on T2*-weighted images, hematoma volume was 
calculated at 30 minutes and 24 hours (III, Figure 1). The boundaries of the hematoma 
were tracked manually (Paravision, Bruker BioSpin, Ettlingen, Germany), the surface 
area on each slice was multiplied by slice thickness, and the values were summed to 
yield total hematoma volume. 
 
Since the hematoma volume was calculated from T2* images, these were used for 
calculation of brain swelling as well. The area of both hemispheres was first outlined 
and calculated on each slice (Paravision), and the areas were then multiplied by slice 
thickness, yielding the total volume of the two hemispheres.  Afterwards, the percentage 
of hemispheric expansion (the volumetric increase of the ICH hemisphere compared to 
the intact one, was calculated (% of hemispheric expansion = [(right hemisphere volume 
/ left hemisphere volume) – 1] x 100). The reliability of this approach was recently 
reported.430 
 
The characteristic hyperintense area on T2-WI, representing brain edema (III, Figure 4), 
was outlined on each slice and multiplied by slice thickness. The values were summed to 
yield total volume. Furthermore, I calculated T2 ratios by dividing the mean T2 signal 
intensity of the hyperintense areas by a reference point outside the brain tissue, a 
method adopted from Del Bigio and coworkers.289 The T2 ratio is reported as the average 
of all hyperintense areas and separately as the average of the perihematomal 
hyperintense rims (III, Figure 5). 
 
Postmortem, hematoma area was calculated at its maximal diameter from the digital 
images obtained after the second MRI round, 24 hours after ICH induction. The 
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hematoma area was outlined and measured with Image J software, and the percentage 
of brain swelling was calculated from the same digital images just as it was from MR 
images. 
 
4.16 Mortality and neurological score 
We scored neurological performance at 24 hours, before re-anesthesia, on a 6-point 
scale,431 comprising 0: normal; 1: contralateral paw paresis; 2: same as 1, plus 
decreased resistance to lateral push; 3: same as 2, plus circling behavior; 4: no 
spontaneous walking, plus depressed level of consciousness; 5: death. 
 
4.17 Statistical analysis 
Data are presented as mean ± SE (I and II) and as mean ± SD (III). Normally 
distributed parametric data sets in multiple groups were compared with one-way ANOVA 
followed by the Holm-Sidak post-hoc test; an unpaired t-test was used in cases of two-
group comparison. Neurological scores in multiple groups were compared with the 
Kruskal-Wallis ANOVA on ranks, followed by Dunn’s post-hoc test; the Mann-Whitney 
rank sum test served for two-group comparison (neurological scores reported as medians 
and individually for each animal). Comparison of mortality versus control values was 
performed with Fisher’s exact test. A two-tailed value of P<0.05 was considered 
significant. 
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5 RESULTS 
5.1 Study I 
 
This study addressed a role for MCs in regulation of BBB permeability, brain swelling, and 
neutrophil infiltration following transient (60 minutes) focal cerebral ischemia in the MCA 
occlusion model. Experiments involved both pharmacological modulation of MCs 
(either blocking or promoting their degranulation) and gene-manipulated MC-
deficient animals. 
 
No significant differences appeared among study groups in physiological parameters 
(MABP, temperature, pH, PaCO2, PaO2, glucose). After MCAO, a transient nonsignificant 
7% reduction, compared with control figures, in MABP in the compound 48/80-treated 
group occurred at 100 min. 
 
To confirm successful MCA occlusion and reperfusion, CBF was monitored by laser-
Doppler flowmetry in three groups of animals: control, cromoglycate, and compound 
48/80. No significant differences in CBF appeared among the study groups at monitored 
time points. 
 
Corrected lesion volumes were similar in experiments with both pharmacological MC 
modulation and gene manipulation (P=0.33 and P=0.41, respectively), with no lesions in 
sham-operated animals, as calculated from TTC-stained brain sections. 
 
Brain sections stained for histopathological evaluation revealed that already in the 
early post-ischemic phase, 4 hours after MCAO, ischemic neuronal necrosis was visible 
(hematoxylin-eosin staining). The sections stained with toluidine blue for detection of 
heparin in MC granules (MCs being the only cell type containing heparin378,379) showed 
that MCs were frequently visible in the vicinity of small cerebral cortical and thalamic 
penetrating vessels, often in widened Virchow-Robin spaces (Figure 2, middle), as 
described earlier.341 In ischemic areas, extracellular granules on the abluminal surfaces of 
blood vessels were accompanied by perivascular edematous changes. Histopathological 
evaluation suggested milder ischemic edematous changes in MC-deficient rats than in 
their WT littermates. 
 
BBB disruption (assessed by magnitude of EB albumin extravasation) was highest after 
treatment with compound 48/80, followed by control figures, and was least in the 
cromoglycate group (Figure 6A). Furthermore, MC-deficient rats showed significantly less 
BBB disruption than did their WT littermates (Figure 6B). In the sham-operated animals, 
no changes occurred in amount of fluorescence between left and right hemispheres 
(P=0.96). 
 
In accordance with level of BBB disruption, the maximum brain swelling was associated 
with compound 48/80 treatment (an 89% increase compared with control) and, again, 
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was least in the cromoglycate group (a 39% decrease compared with control) (ANOVA 
P<0.001). Similarly, MC-deficient rats responded to transient MCAO with 58% less 
ischemic brain swelling than did their WT littermates (P<0.001). No difference appeared 
between the volumes of the right and left hemispheres in the sham-operated animals 
(P=0.71). 
 
Figure 6. Magnitude of Evans blue fluorescent signal representing intensity of albumin 
extravasation and BBB leakage. (A) Pharmacologically modulated groups (cromo=cromoglycate, c 
48/80=compound 48/80). Kruskal-Wallis ANOVA showed a highly significant effect of 
pharmacological modulation (P<0.001); post-hoc tests: *P<0.05, **P<0.01. B) MC-deficient rats 
(WsWs) and their wild-type littermates (WT). *P<0.05 (B). (Figure 2 in I). 
Finally, neutrophil count was up to 2.5-fold higher in the ischemic hemisphere than in 
the non-ischemic one or in sham-operated rats (P<0.05) even at this early (4 hours) 
post-ischemic time point. The lowest neutrophil counts in the ischemic hemisphere were 
in the MC-deficient rats, being only 47% of their WT littermates (P<0.01). Furthermore, 
cromoglycate significantly reduced neutrophil density in the ischemic hemisphere (by 
37%) compared with controls (P<0.01). This difference was most pronounced in the 
infarct core and basal ganglia. Cromoglycate reduced not only the number of emigrated 
neutrophils (P<0.05) but also of those still detectable within the intravascular space 
(P<0.01). 
 
Treatment with compound 48/80 was associated with a clear trend toward enhanced 
neutrophil response, with borderline significance in the area of the basal ganglia (35% 
increase, P=0.06). In sham-operated rats, the pharmacological treatments cause no 
changes in neutrophil counts that would be comparable to the ipsilaterally elevated levels 
in the rats that underwent MCA. 
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5.2 Study II 
 
This study described the involvement of MCs in regulation of BBB damage, formation of 
edema and hemorrhage, and neutrophil infiltration in experiments with TPA. In vitro 
assay of TPA-mediated MC degranulation preceded in vivo MCAO experiments with 
pharmacological modulation of MCs and experiments in MC-deficient animals. 
 
In vitro experiments with TPA showed a dose-dependent release of histamine indicating 
MC degranulation (Figure 7A). TPA-dependent histamine release reached almost 50% of 
the maximal MC degranulation-associated histamine release achieved by the classic MC-
secretagogue compound 48/80. Thus, even small concentrations of TPA, achievable also 
in vivo during therapeutic thrombolysis, strongly stimulated MCs to degranulate and 
release histamine in vitro. 
 
No significant differences emerged in physiological parameters (MABP, temperature, 
pH, PaCO2, PaO2) among study groups. 
 
To confirm successful MCA occlusion and reperfusion, CBF was monitored by laser-
Doppler flowmetry in Experiments 4 (pharmacological modulation with 3 hours of 
follow-up), 5 (pharmacological modulation with 24 hours of follow-up), and 6 (gene 
manipulation with 24 hours of follow-up). No significant differences in CBF appeared 
among the study groups at monitored time points (unpublished data). 
 
Corrected lesion volumes calculated from TTC-stained brain slices were not influenced 
by the treatment assignments in any of the experiments (P ranging from 0.44 to 0.96) 
and ischemic neuronal changes were confirmed by light microscopy of hematoxylin-
eosin-stained tissue sections. 
 
Further histological evaluation showed that TPA treatment was frequently associated 
with erythrocyte extravasation (Figure 7D), generally manifested as a perivascular 
hemorrhagic cuff arising from segmental structural deterioration of the vessel wall 
(Figure 7B), often accompanied by disseminated intraparenchymal hemorrhages. Similar 
to Study I, in sections stained with heparin-detecting toluidine blue, metachromatic 
perivascular cells were found frequently beside cerebral cortical and thalamic penetrating 
vessels (Figure 7C). 
 
Fluorescent evaluation of EB albumin extravasation revealed significantly diminished BBB 
disruption in cromoglycate+TPA-treated animals compared with saline-treated and TPA-
alone-treated ones (Figure 8A). Similarly, MC-deficient rats showed less severe BBB 
disruption than did their WT littermates (Figure 8B). 
 
Furthermore, pharmacological stabilization of MCs and MC deficiency led to significant 
reduction in posththrombolytic brain swelling at all time-points (II, Figure 3A,B)  
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Figure 7. TPA-mediated hemorrhage. A) TPA activates mast cells in vitro. B) Mast cell residing in 
proximity to a blood vessel (arrow). C) Mediator release from activated mast-cell granules. D) 
Multifocal areas of hemorrhage formation in a brain section from a TPA-treated rat. (Republished 
with permission from Duodecim Medical Journal). 
 
Figure 8. Fluorescent signals representing magnitude of Evans blue albumin extravasation and BBB 
leakage. A) Pharmacological stabilization of MCs with cromoglycate (cromo) on BBB permeability 
studied after 3 (ANOVA: P<0.01), 6 (t-test: P<0.01), and 24 hours (ANOVA: P<0.01). B) MC-
deficient rats (WsWs) and their wild-type (WT) littermates (only one animal survived until EB 
albumin administration in the 24-hour WT group). Significance levels of post-hoc (multiple groups) 
or t-tests (two groups): versus saline+saline-treated group: * P<0.05, ** P<0.01, *** P<0.001; 
and pharmacological modulation of MCs versus no modulation in TPA-treated rats: ## P<0.01, 
### P<0.001. (Additional Figure 2, Supplementary online data in II). 
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Parenchymal hemorrhages seen on brain sections (Figure 7D) were quantitatively 
analyzed. TPA caused robust (70- to 100-fold) induction of HF given either before or after 
reperfusion (P<0.001), compared with that of saline-treated controls. Such TPA-
mediated hemorrhage was significantly reduced at 3 (95%, P<0.01), 6 (75%, P<0.01), 
and 24 hours (95%, P<0.05) of follow-up by pharmacological MC stabilization. 
Importantly, genetic MC deficiency supported the role of MCs, leading to 90% reduction 
in TPA-mediated hemorrhage at both 6 (P<0.01) and 24 hours (P<0.001). 
 
Both TPA regimens (either 5 minutes before or 90 minutes after reperfusion) led to a 2- 
to 3-fold increase (P<0.05) in post-ischemic neutrophil infiltration, but the earlier 
infusion had a more substantial effect. Interestingly, a 6-fold increase in neutrophil 
infiltration took place also in the non-infarcted hemisphere. Notably, MC deficiency led to 
a 40% reduction in post-ischemic neutrophil counts compared with their WT littermates 
(P<0.05, all regions counted altogether), similarly in emigrated and intravascular 
neutrophils (data not shown). A comparable reduction was noticed when emigrated 
neutrophils were analyzed separately by region (P<0.01). 
 
Importantly, pharmacological MC stabilization led to significantly (P<0.01) better 
neurological scores at 24 hours (median 2) than for saline-treated (median 3) and 
TPA-alone-treated (median 5) rats. Furthermore, MC-deficient rats had a significantly 
(P<0.05) better neurological outcome (median 1.5) than did their WT littermates 
(median 5). In addition, in pharmacologically modulated groups, 29% mortality 
occurred in the saline-treated group and 64% in the TPA-alone-treated group. No deaths 
occurred in the cromoglycate+TPA-treated group (P<0.05). I observed 17% mortality (1 
dead animal) in the MC-deficient rats, whereas 75% of their WT littermates died 
(P<0.05). 
 
5.3 Study III 
 
Based on the promising results of the previous studies, the possible role of MC 
modulation (pharmacological or genetic manipulation) on edema and hematoma 
growth was examined in an autologous blood injection model of ICH. Further, the 
influence of such effects on the neurological outcome was addressed. 
 
No significant differences arose in the physiologic parameters (MABP, temperature, 
blood glucose, pH, PaCO2, PaO2) between study groups. 
 
Importantly, baseline hematoma volume did not differ among the pharmacologically 
modulated groups (P=0.27). However, hematoma growth during the next 24 hours was 
significantly smaller after both iv and icv MC stabilization than in saline-treated controls, 
as analyzed from MRI (P<0.001) and ex vivo obtained digital images (P=0.02). 
Hematoma growth in the compound 48/80 group was not different from that of the 
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control group (P=0.28), but it was significantly larger than both cromoglycate groups 
(both P<0.001) in all-pairwise comparison. Furthermore, hematoma volumes in the MC-
deficient rats, although being almost significantly larger at baseline than for their WT 
littermates (P=0.059), showed significantly smaller growth during 24 hours (P=0.04). 
Similarly, based on the data from ex vivo images, hematoma volumes were larger in the 
WT littermates than in the MC-deficient rats (P<0.01). 
 
Brain edema volumes calculated from the hyperintense areas of T2 images at 24 
hours were significantly smaller in both cromoglycate groups than in the saline and 
compound 48/80 groups (P<0.001), demonstrating a 25% increase in the control and a 
46% increase in the compound 48/80 group and approximately a 15% reduction in both 
cromoglycate groups during 24 hours. Experiments with genetically modified animals 
revealed that T2-based brain edema calculated at 24 hours was significantly smaller in 
the MC-deficient rats than in their WT littermates (P=0.036), representing a 10-fold 
higher increase in the WT littermates compared with the MC-deficient rats during 24 
hours. 
 
Furthermore, in the pharmacologically modulated groups, brain swelling (hemispheric 
expansion seen on T2*-WI) was, compared with controls, significantly smaller in both 
cromoglycate groups and significantly larger in the compound 48/80 group even at 
baseline (P<0.001). This difference was further magnified after the next 24 hours 
(P<0.001), with brain edema being 75% smaller in the icv cromoglycate, and 48% 
smaller in the iv cromoglycate group, and 61% larger in the compound 48/80 group than 
in controls. The difference in brain swelling at 24 hours was even significantly smaller in 
the icv cromoglycate group than in the iv cromoglycate group (P<0.05). MC-deficient rats 
developed 42% less brain swelling than did their WT littermates after 24 hours 
(P=0.035), although it was somewhat larger at baseline. Similarly, the percentage 
change in brain swelling between baseline- and 24-hour values was significantly smaller 
in the MC-deficient rats than in the WT ones (P<0.05). 
 
In line with these described MRI-derived observations, planimetric data obtained after 24 
hours from the digital images of ex vivo tissue slices revealed 83% less brain swelling 
(hemispheric expansion) in the icv cromoglycate, 63% less brain swelling in the iv 
cromoglycate, and 50% more brain swelling in the compound 48/80 group than in the 
controls (P<0.001). Similar calculations showed 87% less brain swelling in the MC-
deficient rats than in their WT littermates at 24 hours (P <0.001). 
 
Neurological scores obtained at 24 hours were highly significantly (P<0.001) better 
after MC stabilization (median 1 for both routes of administration) compared with the 
control (median 4) and compound 48/80 (median 5) groups. The neurological outcome of 
MC-deficient rats (median 1) was significantly (P<0.001) improved compared to their WT 
littermates (median 3). Mortality at 24 hours was 45% in the control group, 0% in both 
cromoglycate groups, and 55% in the compound 48/80 group. No deaths occurred in the 
MC-deficient group, whereas the WT rats experienced 25% mortality. 
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6 DISCUSSION 
6.1 General discussion 
 
Stroke (ischemic and hemorrhagic), a leading cause of death and disability worldwide, 
consumes a significant portion of the material and immaterial resources available for 
health care in general. The principal cause of clinical deterioration and premature death 
following large ischemic hemispheric strokes is brain swelling, increased ICP, and 
distortion of the brain structures, herniation. Several approaches to fight malignant brain 
swelling clinically are based on empirical support, but scientific evidence for their efficacy 
is lacking. At present, invasive surgical decompressive craniectomy and hypothermia 
seems to be promising. 
 
Thus far, thrombolysis with intravenously administered TPA is the only proven 
pharmacological therapy for acute ischemic stroke, although, its application is associated 
with risk for clinically relevant parenchymal hemorrhage. Fear of hemorrhage may be 
a reason for withholding this otherwise beneficial treatment from a large proportion of 
patients. A critical step in the formation of edema and hemorrhage is disruption of the 
basal lamina and the BBB. These detrimental processes may be aggravated by 
inflammatory responses, which may be further promoted by therapeutically administered 
TPA. 
 
In contrast to ischemic stroke, no medical or surgical treatment has thus far been 
efficacious in primary intracerebral hemorrhage, the poor outcome of which is mainly 
due to the mass effect of the growing hematoma and edema. Furthermore, the 
hematoma itself induces secondary inflammatory changes. Clearly, novel 
pharmacological discoveries are needed for the acute stage to improve long-term 
outcome of the victims. 
 
Studies included in this thesis addressed the possible role of MCs in experimental 
ischemic and hemorrhagic stroke. MCs are resident cellular mediators of immediate 
hypersensitivity and initiate local phlogistic reactions to mechanical, toxic, and allergic 
stimuli. They are tissue-based cells and occurred in several end-organs, including the 
brain. Their metachromatic granules contain potent preformed vasoactive, proteolytic, 
anticoagulant, and chemotactic substances. We and others341,352 have observed MCs 
positioned abluminally to the basal lamina and BBB (I, Figure 1A,B). In pilot studies,409 
MC density and their state of granulation were altered early following focal transient 
cerebral ischemia, and MCs were frequently found degranulating in association with 
edema and hemorrhage formation. 
 
These findings, together with the characteristic perivascular location of MCs and the 
ability of their proteases to degrade the basement membrane proteins,17,18 led to the 
hypothesis that following transient focal cerebral ischemia, MCs may be involved in the 
regulation of BBB permeability, brain swelling, TPA-mediated cerebral hemorrhage, and 
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inflammatory cell (neutrophil) infiltration. Finally, since the mass effect of a growing 
hematoma and edema is associated with poor outcome after primary ICH, I studied 
whether MC blocking would exert a therapeutic effect in an experimental ICH model. 
Apart from pharmacological modulation of MCs, I induced focal cerebral ischemia and ICH 
in a genetically manipulated MC-deficient rat strain. In addition, in vitro tests of TPA-
mediated MC degranulation were performed. 
 
Briefly, these results demonstrate MC’s mediation of BBB permeability, brain swelling, 
and neutrophil accumulation following focal transient cerebral ischemia (I). Furthermore, 
in the same model, MCs were found to be involved in formation of hemorrhage 
associated with the application of TPA, and that hemorrhages and eventual unfavorable 
outcomes were reduced by cromoglycate treatment (II). Finally, MCs were shown to 
regulate the growth of hematoma and edema in ICH (III). Importantly, also here the 
pharmacological and genetic modulations of MC effects described were related to 
neurological performance and rates of fatal outcome. 
 
6.2 Mast cell mediation of BBB permeability, brain swelling, and neutrophil 
infiltration after focal transient cerebral ischemia (I) 
 
Studies with the MCAO model demonstrated that cerebral MCs participate in the 
regulation of early post-ischemic BBB disruption, brain swelling, and neutrophil 
infiltration. Pharmacological stabilization of MCs reduced these outcome measures, 
whereas pharmacological augmentation of MC degranulation had the opposite effect. 
Moreover, the experiments with MC-deficient rats confirmed the specific role of MCs in 
this scenario. 
 
Although the precise mechanism of MC activation in ischemia remains unclear, it may 
possibly be launched by the blood serum-derived activated complement proteins C3a and 
C5a, since mixing of serum with CSF in vitro as well as plasma extravasation after BBB 
damage in clinical stroke and in SAH leads to fast activation of these anaphylatoxins 
which are potent stimulators of MCs.432 MC granule constituents (especially histamine, 
heparin, and bradykinin), in turn, show significant microcirculatory effects, and 
modulation of their liberation during ischemia may influence the extent of the damage. 
 
What is striking is that extravasation of EB albumin was in direct correlation with degree 
of expansive cerebral swelling even a few hours after reperfusion (I, Figure 4), 
suggesting that, even during the very early (ultra-acute) phase of ischemic stroke, 
vasogenic volumetric enlargement is a very dominant mechanism of brain edema in 
this model. This is important for the future design of anti-edema therapies since it has 
been widely held that interventions targeting the vascular wall and basal lamina may not 
be of enormous importance at the ultra-acute stage, when the cytotoxic mechanism of 
brain edema has been considered to be at its peak. 
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Accordingly, digestion of the endothelial basal lamina occurs as early as 2 hours after 
ischemia.84,85 Such loss of microvascular integrity may link blood-protein and blood-
cell extravasation to edema and hemorrhage formation.71,84 A large body of evidence 
(section 2.1.3) indicates that proteases are involved in this process. Furthermore, MMP-
mediated disruption of the tight junction proteins occludin and claudin occurs, and the 
MMP inhibitor already reduces the BBB damage 3 hours after transient focal cerebral 
ischemia.94,96 These results also support the likelihood of rather early BBB disruption 
after transient MCAO. 
 
Besides vasolytic and anticoagulant properties, I propose five lines of MC involvement in 
these processes: First, cerebral MC-derived chymase341 is a potent protease which 
cleaves fibronectin and also activates procollagenases.18,387 This happens even in the 
presence of TIMP-1433. A key role for MC chymase in the activation of pro-MMP-2 and 
pro-MMP-9 was demonstrated and confirmed recently.385 Second, another MC-derived 
protease, tryptase, is also able to activate MMPs.386 Third, MCs themselves can release 
the gelatinases A (MMP-2) and B (MMP-9),109 and both MC-derived chymase and 
tryptase can degrade TIMP-1 protein,88 suggesting a role for MCs in regulation of this 
proteolytic system. Fourth, MC granules contain cathepsin G, which is able to cleave 
many components of the extracellular and pericellular matrix, including fibronectin and 
vitronectin.390 The role of cathepsins in microvascular matrix degradation has been 
reported.86 Finally, apart from proteases, MCs can release various cytokines (e.g., TNF-
α and IL-1) shown to be involved in upregulation of MMPs434 and in edema 
formation.435,436 Indeed, MCs do possess a potent armamentarium to target the 
components of the BBB and basal lamina shortly after their activation, whereas de novo 
production of these and additional mediators reactivates and maintains the process. 
 
In addition to the BBB disruption and brain swelling, RI includes the release of free 
radicals and inflammatory mediators promoting leukocyte infiltration. Neutrophils start 
to accumulate within hours after reperfusion at the ischemia site,181,437 a process which 
also occurs in the human brain.167 In this inflammatory response, current data suggest 
MC participation (I, Figure 5). Clinical trials based on inhibition of neutrophils have had 
no success (section 2.1.3.3) perhaps explained by the fact that leukocytes arrive too 
late166 to influence damage-propagation in viable, non-apoptotic neural tissue, or by 
adverse reactions to heterologous protein.203 
 
The extremely potent resident (hence already present at the very outset of ischemia) 
proinflammatory MCs may offer an alternative and more proximal target for early 
antichemotactic intervention before the involvement of any circulating inflammatory cells. 
The fact that MC stabilization was associated with reduction in both the number of 
transmigrated neutrophils and of those still within the intravascular space (I, Figure 5B, 
right) suggests a role for MCs not only in reducing passive neutrophil trafficking through 
BBB breaches, but probably also in attenuating the perivascular chemotactic gradient up 
which blood-borne neutrophils start to transmigrate. Indeed, tissue-based MCs release 
potent mediators (PAF, TNF-α, IL-4, IL-5, IL-8 and neutrophil, eosinophil, and 
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macrophage chemotactic factors) known to attract inflammatory cells. Moreover, MC-
derived histamine regulates expression of selectins in ECs with consecutive rolling of 
leukocytes376 and plays a role in translocation of P-selectin to the cell surface,438 further 
revealing the proinflammatory character of MCs. Traditionally, the main cerebral cellular 
sources of these chemotactic mediators include ECs, astrocytes, microglia, and neuronal 
cells, but the present work adds MCs to this list also within the cerebral ischemic 
cascade. 
 
In this study, infarct volumes were not influenced by the MC interventions; this was 
expected at this early post-ischemic time point and by the fact that we tested a drug, 
sodium cromoglycate, without any known direct neuroprotective properties. Importantly, 
experiments performed after sham surgery and pharmacological MC modulation suggest 
that the changes observed were related to the ischemic response rather than to the 
pharmacological effects alone. Furthermore, the pharmacological manipulations seemed 
to cause no significant influence on post-ischemic CBF that could have mediated the 
effects observed. 
 
Thus far, the MC as a regulator of BBB has not been widely recognized. Current 
experiments imply the strong involvement of this multi-active and potent cell type (with 
an armory of bioactive granule mediators able to target vascular basal lamina) in early 
BBB failure and brain swelling following focal transient cerebral ischemia. Furthermore, 
stabilization of MCs may provide an early opportunity to prevent infiltration of other 
inflammatory cells and their consequences such as no-reflow and further release of free 
radicals, all of which enhances vascular damage. Since the MCs respond rather 
stereotypically with degranulation of multi-active mediators to a variety of physico-
chemical environmental and disease-associated challenges, MC stabilization could be a 
promising avenue of research also in conditions other than ischemic stroke. 
 
6.3 Mast cell regulation of TPA-mediated hemorrhage formation after focal 
transient cerebral ischemia (II) 
 
Hemorrhages, together with other components of the vascular RI (the BBB disruption, 
brain swelling, and neutrophil infiltration), can devastate a good prognosis following 
successful stroke thrombolysis. Although herniation and edema were once not considered 
a major problem in TPA-treated patients,56 the European Cooperative Acute Stroke Study 
reported herniation- and brain edema-related mortality to be higher than hemorrhage-
mediated mortality, and to be more prevalent in the TPA group.439 Furthermore, cerebral 
bleedings do occur in patients undergoing thrombolytic treatment for acute myocardial 
infarction and pulmonary embolism, as well. Fear of post-thrombolytic hemorrhage leads 
to withholding of this beneficial therapy from number of patients. 
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The mechanism of post-thrombolytic hemorrhage is generally not understood, but it 
occurs with all fibrinolytic substances such as TPA, streptokinase, prourokinase, and 
reteplase,440,441 all of which invariably induce plasminemia.442 Plasmin, in turn, is a multi-
active substance with proinflammatory activity (section 2.1.3.2); it degrades a range of 
ECM proteins and activates MMPs, which in turn digests matrix proteins443 and causes 
brain tissue damage.102,444 
 
In addition to proteolytic mechanisms of BBB disruption, BBB damage (leading to 
erythrocyte extravasation) may be mediated by the numerous preformed MC-mediators 
influencing vascular permeability (e.g., histamine and bradykinin). Perhaps more 
important in the setting of thrombolytic therapy for cerebral ischemia, hemorrhage 
development may be further promoted by a strong anticoagulant, heparin, which is 
produced in mammals by MCs only.378,379 Heparin released locally from perivascularly 
positioned MCs may stop the formation of hemostatic plugs to patch BBB breaches to 
prevent erythrocytes extravasation, thereby contributing to hemorrhagic events. 
Interestingly, activation of the fibrinolytic system was found in dogs with MC tumors and 
a similar effect in dogs was achieved after very high levels of MC secretagogue 
compound 48/80 application,445 confirming the fibrinolytic potential of MC mediators. 
 
In sum, the present work, as extrapolated from Studies I and II, is in agreement with the 
recent suggestion that formation of hemorrhage may represent the end stage of a 
cascade that started as vasogenic edema following the BBB disruption,446 as suggested 
even earlier.71,84 The data in Study II support the fact that TPA aggravates all of these 
phenomena. In vitro experiments demonstrate that TPA by itself degranulates MCs to a 
great degree, a finding not reported for any other fibrinolytic drug thus far. Future 
studies should examine whether this is a class effect for all serine protease 
thrombolytics. Importantly, based on the present data, these phenomena may not only 
be modulated by targeted genetic MC manipulation but also be prevented by MC 
stabilization; this may identify a therapeutic pharmacological target. This study therefore 
establishes a novel cellular mechanism underlying these catastrophic phenomena. 
 
In the present work, neutrophils were largely intravascular, but the count of neutrophils 
already having emigrated into the brain parenchyma was also significantly elevated by 
TPA (data not shown). This occurrence was influenced by MCs. Besides the possible 
mechanism discussed in the previous section, the proinflammatory effect of TPA may 
be mediated by plasmin, which is able to induce the synthesis of PAF and activates the 
terminal complement cascade.447 Furthermore, when injected into the brain, it recruits 
neutrophils.444 Interestingly, after TPA treatment, a consistent increase in neutrophil 
infiltration occurred not only in the ischemic but also in the intact hemisphere (II, Figure 
4A). This suggests an independent proinflammatory effect of TPA which has been largely 
overlooked but may be clinically relevant. The intrinsic proinflammatory effect (increased 
neutrophil emigration) of TPA in the non-ischemic brain portions appeared also in 
experiments with pharmacological MC modulation (unpublished data). If the in vitro TPA-
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mediated MC degranulation can be reproduced also in vivo, this could in part explain this 
very phenomenon. 
 
Since we focused on the untoward post-reperfusion effects of TPA rather than therapeutic 
recanalization, TPA did not reduce infarct size. To have better control over the 
reperfusion per se, we used the suture occlusion and not the blood clot model. The 
suture model was utilized in experiments studying the effect of TPA on RI and formation 
of hemorrhage.153 In that work, reperfusion 6 hours after filament MCA occlusion was not 
associated with hemorrhage in experiments without TPA (a finding similar to that of 
Study I), whereas the same experiment with TPA treatment was associated with 
hemorrhage; this shows the utility of the suture model in studying reperfusion-mediated 
hemorrhage. 
 
The results show, indeed, the MC as a largely fibrinolytic cell type in the microvascular 
milieu. This, in the light of current results, clearly potentiates the unwanted side-effects 
of therapeutic thrombolytics after ischemic stroke. Pharmacological stabilization of MCs is 
therefore a potential novel adjuvant therapy to prevent the occasional devastating 
complication from thrombolytics after ischemic stroke as well as after acute myocardial 
infarction and pulmonary embolism. 
 
6.4 Mast cell regulation of growth of hematoma and brain swelling in 
experimental intracerebral hemorrhage (III) 
 
This study demonstrated that pharmacologically induced inhibition of MC degranulation 
led to significant reductions in hematoma volume and brain swelling at 24 hours after 
the induction of experimental ICH, whereas pharmacologically stimulated MC 
degranulation produced the opposite effect. The specific role of MCs in this response was 
confirmed by experiments in MC-deficient rats and their WT littermates. These results 
translated into neurological outcome and mortality in favor not only of MC deficiency but 
also pharmacological MC stabilization, supporting the association between mass effect of 
hematoma and of swelling and poor outcome after ICH. 
 
Clinically, relentlessly progressing cerebral edema causes neurological deterioration as 
early as within 24 to 48 hours after ICH,6 often leading to displacement of brain 
structures, increased ICP, and fatal outcome233—as supported also by the present 
findings. Extensive experimental studies of the pathophysiology of ICH-associated edema 
revealed a role for blood degradation products (specifically thrombin) and MMPs (section 
2.2.1). Although the precise cellular pathomechanisms of brain edema formation after 
ICH are still not well established, Study III contributes to the list of potential causes of 
hazardous expansive tissue displacement and mortality from ICH, specifically, 
degranulation of MCs and the ensuing liberation of vasoactive, anticoagulant, and 
proteolytic substances. 
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However, despite the information gathered in the present studies, the particular 
pathophysiologic basis of MC-dependent brain edema and swelling during ICH remains 
essentially speculative. It may depend on the release of a host of MC-derived vasoactive 
substances (histamine, bradykinin) and proteolytic enzymes (tryptase, chymase), which 
may cause increased vascular permeability. As with ischemia, this may disrupt the basal 
lamina of the vasculature along with the surrounding extracellular tissue matrix, leading 
to secondary aggravation of extravasation of blood cells and of plasma proteins. 
 
Moreover, MC-derived chymase and tryptase both activate MMPs, which may further 
contribute to the disruption. Results from our previous studies in focal transient cerebral 
ischemia would support the concept of MC-dependent induction of local breaches in BBB 
that could occur also in perihematomal zones and thereby contribute to the expansive 
edema formation in ICH. In view of the MC activation by TPA in vitro, it is of interest that 
PAs potentiate thrombin-induced brain edema,448 and that—in an experimental setting—
TPA used to liquefy the hematoma causes massive edema and inflammation.449 
 
Apart from the possible role for the mentioned MC mediators, MC-mediated cytokines 
(e.g., TNF-α and ILs) may be involved as well. Some human studies show a correlation 
between plasma concentration of TNF-α and IL-6 (both belonging among MC mediators) 
and magnitude of perihematomal brain edema and hematoma growth.254,257 In all 
likelihood, we are dealing with the mainly multifactorial basis of ICH-related brain 
expansion. 
 
Hematoma expansion has also been attributed to continuing bleeding from the primary 
source and to mechanical disruption of the surrounding vessels.6 In addition to direct 
tissue-compressing effects and secondary microcirculatory failure, these effects could 
also trigger local MC degranulation and activation in the perihematomal zone. This view 
is compatible with recent evidence suggesting that secondary growth of ICH may result 
from secondary bleeding within the peripheral zone around the ICH.450 
 
Although thrombin is considered to be involved in the pathophysiology of ICH-associated 
edema formation, thrombin inhibitors did not succeed in reducing hematoma size.273 To 
add another mechanism to the causes of secondary bleedings, MC-derived heparin 
may, in theory, prolong blood extravasation and also promote secondary hemorrhages, 
especially in areas where the BBB has been compromised by extravasated blood 
components and their vasoactive derivatives. This hypothesis is in line with the present 
data showing significant growth of the hematoma after augmented MC degranulation 
(with compound 48/80) and in non-treated control animals, and with the absence of 
hematoma growth after MC stabilization and in MC-deficient rats. 
 
The present results and the mechanisms suggested to explain them support the role of 
MCs in regulating hematoma and edema growth after experimental ICH. Such regulation 
translated into neurological outcome and mortality. This makes pharmacological MC 
modulation interesting for development of clinical strategies to prevent space-occupying 
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edema and hematoma growth early after the onset of ICH, especially with no medical 
and surgical treatment for this devastating condition yet proving effective. 
 
6.5 A place for MCs in the neurovascular unit? 
 
The integrity of the microvasculature is provided not only by the BBB and the basal 
lamina, but by various components of the neurovascular unit (Figure 2, center), as well. 
Complex interactions between cellular and extracellular components within the unit 
involve matrix adhesion receptors, the integrins, and dystroglycan (section 2.1.3). 
 
MCs show several types of interactions—some of which still remain speculative—with 
constituents of the neurovascular unit. 
 
Astrocytes During development, MC association with the vascular bed (preferentially at 
branching points) is dependent on contact of the blood vessel with astroglial processes. 
This adhesion to the vascular wall involves MC-expressed α4-integrins.353 Mature MCs can 
be grown on astrocytes,339,451 and astroglial processes elongate in close proximity to 
MCs.335 MC cytoplasm, in turn, extends into the neuropil.351 Adjacent astrocytes can 
influence the phenotype and the migration of MCs,346 presumably synthesizing MC growth 
factors such as IL-3347,348 and NGF.349 
 
Neurons Mast cell products enter neurons at least in three ways (transgranulation) in 
the dove brain370: a) direct fusion of the granule and plasma membranes of both mast 
cell and neuron; b) engulfment of mast cell processes containing granules or capture of 
released granule remnants; and c) receptor-mediated endocytosis. Interestingly, the 
frequency of transgranulation events is related to the activity status of the mast cell. 
 
Endothelial cells Changes in endothelial cell-matrix interactions may be influenced by 
TNF-α and IL-1β,452 most likely by down-regulation of integrin receptors of the β1 
subfamily.453 Accordingly, TNF-α reduces ECs’ integrin α1β1 expression, leading to 
decreased adhesion to laminin,453 whereas IL-1β contributes to early ischemic brain 
edema, presumably by altering β1 expression.
436 Both cytokines can be released by 
different cells, but belong among MC mediators, as well. 
 
Basal lamina and ECM MCs can attach to and migrate on laminin- and fibronectin-
coated surfaces.362 Furthermore, MCs’ surface receptors (one of them for laminin) 
regulate MC trafficking and distribution by engaging ECM components, including the 
classical integrin receptors.361 
 
Considered together, these data suggest some kind of biologically and 
pathophysiologically relevant interactions between MCs and the neurovascular unit, an 
idea apparently not previously suggested. 
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7 SUMMARY AND CONCLUSIONS 
 
The present work on focal transient cerebral ischemia with pharmacological and genetic 
modulation of MCs demonstrates that cerebral MCs participated in regulation of early 
BBB disruption, brain swelling, and neutrophil infiltration. That not only genetic MC 
deficiency but also pharmacological interventions targeting MCs showed similar results 
suggests a potential novel therapeutic approach to be studied in cerebral insults, where 
tissue injury is followed by florid extravasation, hazardous brain swelling, and 
inflammatory cell infiltration. The importance of such an approach is supported by the 
fact that no effective medical treatment exists for malignant brain swelling after large 
hemispheric strokes. 
 
The efficacy of the same approaches was reproduced in association with TPA-mediated 
hemorrhage. Furthermore, TPA was found to degranulate MCs in vitro, an observation 
worth noticing by the manufacturers of thrombolytic compounds. Since the key findings 
also translated into improved neurological outcome and reduced mortality, they are 
relevant to the understanding and prevention of the occasional devastating complications 
following administration of thrombolytics (acute ischemic stroke, acute myocardial 
infarction, pulmonary embolism). If found useful also in humans, the safety of 
thrombolytic therapy could improve, so that more stroke patients could receive this 
beneficial treatment. 
 
Since neither medical nor surgical treatment has been beneficial in primary ICH, 
findings of reduced hematoma and edema growth and of improved neurological outcome 
as well as of reduced mortality associated with MC stabilization suggest that it is an 
interesting, novel therapeutic avenue also in this life-threatening condition. All these 
antihemostatic effects, superimposed on the vasculopathic proteolytic capacity, 
emphasize the fibrinolytic properties of MCs in both ischemic and hemorrhagic brain 
insults, properties that could well be utilized in future research. 
 
Future studies on this subject could also include more detailed dissection of the 
mechanism underlying MC-mediated BBB disruption and its consequences, as well as 
elucidation of how, exactly, MCs influence hemorrhage and edema growth in ICH. Of 
further interest would be the nature and behavior of particular MC mediators during 
ischemia, since some of these may also serve in tissue protection. For instance, 
histamine release may promote vasodilatation in areas of secondary microcirculatory 
ischemia. Further work might involve application of MMP antagonists, antihistamines; 
more detailed morphological studies of the early BBB opening after ischemia could reveal 
the interplay of MCs with other components of the neurovascular unit at different points 
during evolving brain damage. 
 
Since brain edema is a key contributor to increased mortality and morbidity in numerous 
brain conditions apart from stroke, further study would be useful in the area of brain 
trauma, brain tumors, and infections. However, the most important task is to examine 
    
83 
whether any of these promising data can be translated into human medicine, since 
differences arise in the biological tasks of MCs among species. It is possible that the 
cerebral MCs are less abundant in humans and may possess a different operative 
repertoire than in rodents. 
 
Cromoglycate, the model compound, is a well-known and safe drug used topically for 
decades for allergic clinical conditions. However, for purposes of the present work, the 
fact that it has presumably too low penetration through the BBB presents a problem that 
needs expertise from those in, for example, the pharmaceutical industry. However, the 
observation that intravenously administered cromoglycate in an ICH model showed the 
same positive effects as did intracerebroventricular application might speed its 
translation into human trials. 
 
Another limitation of this study is that only one model compound was used to 
substantiate the utility of MCs as a pharmacological target for limiting deleterious effects. 
Moreover, the issue of appropriate dosages must be further addressed. 
 
Novel therapeutic strategies are necessary to prevent loss of microvascular integrity. 
Interactions within the neurovascular unit are complex. This calls for interventions at 
multiple levels (e.g., those between individual mediators and their target receptors or 
structures, and the level of cellular activation and interactions) rather than a single-
impact molecular target approach. Such a single-pathway approach (glutamate release, 
calcium antagonism, free radical release) prevailed in recent failed clinical trials of 
neuroprotective agents in ischemic stroke. 
 
MCs reside in the pivotal perivascular position and contain an abundance of vasoactive, 
proinflammatory, anticoagulant, and proteolytic mediators. Hence, MC stabilization 
may represent a multiple-level strategy, blocking simultaneously several 
molecular cascades that participate in progressive tissue damage instead of 
blocking just one single pathway. The present results propose the MC to be 
considered an essential player in the neurovascular unit, where it contributes to cell-cell 
and cell-matrix interactions as well as controls vascular permeability and participates in 
recruitment of blood-derived inflammatory cells. 
 
To reproduce the findings of these studies in human disease—to reduce suffering after 
large hemispheric strokes and intracerebral hemorrhages as well as to improve the safety 
of thrombolysis—is my earnest intention. 
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